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1. Introduction
1.1 Acute myeloid leukaemia and the folate receptor as a target for drug delivery
1.1.1      Acute myeloid leukaemia (AML): Disease characteristics and current  
treatment strategies
Acute leukaemia is a cancer where haemopoietic blasts cells constitute more than 20% of the bone 
marrow or peripheral blood cells; usually accumulating in the blood, infiltrating other tissues and 
causing bone marrow failure (1-3). Two main groups of acute leukaemia exist: acute lymphoblastic 
leukaemia (ALL) and acute myeloid leukaemia (AML) (1, 3). The focus in this master thesis will be 
on AML.
Figure 1.1: Hematopoiesis. Picture from (4). CLP = common lymphoid progenitors, CMP = 
common myeloid progenitors. AML arises from the CMP compartment (3).
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AML is an uncommon cancer (3, 5), and in the US, UK and Norway about 12000 (6), 1000 
(1), and 100 (7) new cases are diagnosed each year, respectively. The disease occurs at all ages but 
is most common in the elderly; the median age of presentation being in the late 60s (1, 5). Clinical 
manifestations include dyspnoea, weakness, infections and bleeding due to bone marrow failure 
syndrome producing anaemia, granulocytopenia and thrombocytopenia (8). AML is a highly 
heterogeneous disease clinically and biologically, with eight WHO sub-classifications (2008) based 
on morphology, immunophenotype, cytochemistry and cytogenetics (1-3, 5, 6). The MOLM-13 cell 
line used in this master thesis is classified as M5a (acute monocytic leukaemia) according to the 
French-American-British (FAB) AML classification (9), which is based on differentiation level and 
morphologic evaluation of blasts (3). Cytogenetic and molecular changes are highly prognostic 
indicators in AML, and patients can be defined to be at favourable, intermediate or unfavourable 
risk based on this information (1, 2, 5, 6). Acute promyelocytic leukaemia (APL), FAB 
classification M3 (3, 7), is often considered in an own category, given that this AML subtype has a 
different treatment regime and a more favourable treatment outcome (3, 10). APL will not be 
discussed further in this thesis. The risk-stratification allows for better treatment planning for AML 
patients (6). Usually, AML is fatal within weeks from the time of diagnosis if it is left untreated (8).
AML therapy is primarily divided into two phases; remission induction and post-induction 
therapy (1, 5-7, 11). The treatment approach depends on the age of the patient (2, 5). Treatment of 
childhood AML will not be described here. The standard remission induction therapy in adults has 
not changed much over several decades, and treatment outcomes remains suboptimal (6). Also, 
several novel and targeted agents have failed to improve patient outcomes in randomised trials (11). 
Relatively few new AML drugs have been approved in the past 20 years (5).
For patients between 18 and 60 years old, the standard of care for induction therapy remains 
a combination of 3 days of daunorubicin and 7 days of cytosine arabinoside (cytarabine), also called 
the “3 + 7” protocol (2, 3, 5, 11). In this regime, cytarabine (100 – 200 mg/m2/day) is given as a 
continuous IV infusion over 7 days and an anthracycline, normally daunorubicin (45 – 90 mg/m2), 
is given as an IV infusion for the first 3 days (2, 3, 6, 7). Cytarabine acts as a competitive inhibitor 
of DNA polymerase, and it can also act as a substrate for the enzyme; incorporation leading to chain 
termination or preventing DNA replication (12). Daunorubicin is described thoroughly in section 
1.3.3. Addition of other agents or multidrug resistance modulators has not improved outcomes for 
induction chemotherapy (2, 6). Complete remission (CR) is defined as marrow blasts lower than 5% 
and recovery of peripheral counts, and is assessed after one or two induction treatments (5). The 
aim of remission induction is CR, but without further treatment after reaching CR a very high 
proportion of the patients will relapse (3, 5). Therefore, post-induction therapy is necessary (3, 5). 
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For patients younger than 60, this consists of further chemotherapy or stem cell transplantation 
(SCT) (5, 6). High-dose cytarabin 3 g/m2 per 12 hours on day 1, 3 and 5 given for a total of 4 
courses is the most widely accepted schedule, particularly for favourable risk patients (5-7). SCT 
from a well-matched sibling donor is an alternative approach, and offers the best option for 
unfavourable risk patients (2, 5, 6). The current treatment outcome is that 40 to 45% of AML 
patients younger than 60 years will be cured (5).
The majority of AML patients, however, are older than 60 years (5). Lower CR rates can be 
predicted in older patients based on prognostic factors such as increasing age, poor performance 
status, comorbidities, secondary leukaemia, P-glycoprotein (P-gp) overexpression leading to 
chemotherapy resistance, adverse cytogenetics, splenomegaly and extramedullary disease (2, 3, 5). 
Induction therapy is less effective in older patients due to patient-related and disease-related factors 
(6). Disease-characteristics associated with poor outcome occur more frequently in older patients (2, 
6). Also, intensive chemotherapy treatment is problematic due to toxicity concerns (5, 7). Low-
intensity induction with low-dose cytarabin has been a standard treatment over the last several 
decades, aiming to preserve efficacy while reducing toxicity in older patients (2, 11). However, for 
selected elderly patients intensive remission induction therapy, hence a 3 days of daunorubicin (45 
to 50 mg/m2) and 7 to 10 days of cytarabine (100 to 200 mg/m2) regime, provides a superior 
approach to a wait-and-watch or dose-attenuated cytoreductive treatment (2, 5, 11). CR after 
remission induction is normally short-lived in the elderly, and there is no established post-induction 
therapy for these patients (2, 5). For patients at least up to age 70 who reach CR, an option is 
reduced-intensity conditioning and SCT (6). Currently, several novel agents are under investigation 
for treatment in older AML patients, including clofarabine, decitabine, azactidine and tipifarnib (6). 
The overall survival probability for patients older than 60 years is around 10% 5 years from the 
diagnosis (5). 
Patients that are not fit for intensive treatment because they are medically unfit or unlikely to 
benefit from treatment due to the nature of their disease have been treated with low-dose cytarabin, 
hydroxyurea, hypomethylating agents or supportive care (2, 5). 
10
Figure 1.2: Overall AML survival in patients. Data from 3766 patients with newly diagnosed AML 
referred to the Leukaemia Department of the M.D. Anderson Cancer Center from 1973 to 2008.  
Picture from (13).
A 1975-2001 annual US report on cancer stated that AML remains a highly fatal malignancy 
(14). The 5-year relative survival was improved from 6% to 17% over 20 years, and this was stated 
to may be attributed in part to supportive care improvements (14). See Figure 1.2 for overall AML 
survival in different treatment eras. 
The majority of AML patients will die from their disease. This warrants for the investigation 
of new and more effective treatment approaches. In the following section, the folate receptor is 
described as a target for drug delivery in AML.
1.1.2      The folate receptor and its role in AML targeted drug delivery
Vitamin B9 is a co-enzyme that occurs physiologically in reduced forms, of which folate is one (15, 
16). Reduced folates have essential roles in one-carbon transfers and in biological methylation 
reactions (17, 18). At least three different transporters mediates cellular folate uptake (15, 17). The 
reduced folate carrier (RFC) is the predominant transporter, mediating transmembrane transport of 
5-methyltetrahydrofolate and is expressed throughout development and in normal adult tissues (15, 
17, 19). A proton-coupled high-affinity folate transporter has been shown to be the major transporter 
of folate under low pH conditions and for intestinal absorption of the vitamin (15, 17, 20). The third 
folate transporter is the folate receptor (FR), a high-affinity folate binding protein that binds folic 
acid (FA) as well as reduced folates, antifolates and folate conjugates (15, 16). Compared to the 
RFC, FRs have a more than 103 fold higher affinity for folate and have a highly restricted 
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expression among tissues (19). At least 4 isoforms of FRs exists; α, β, γ/γ' and δ, and the isoforms 
share 68 – 79% sequence identity (15, 16, 19). The α, β and δ isoforms are cell surface glycosyl 
phosphatidylinositol (GPI)-anchored membrane proteins, whereas γ/γ' isoforms are constitutively 
secreted (19). The literature to date has mostly been focused on FR-α and FR-β (19). FR-α and FR-
β are N-glycosylated proteins with affinities for folic acid in the nanomolar range (Kd ~ 0.1 – 1 nM) 
(15, 19).
The expression of functional FR is low or absent in normal tissues (16, 19). The FR-α 
isoform is expressed in the luminal surface of polarised epithelial cells and also on epithelial cells in 
the kidney proximal tubules (15, 19). The epithelial cells have limited accessibility from the 
bloodstream, and larger folate conjugates, like nanocarriers, are not accessible to the kidneys due to 
their inability to be filtered through the glomerulus (15, 19).
The FR-β isoform is expressed in normal myelopoiesis and is a differentiation marker in the 
myelomonocytic lineage (15, 16, 19). It is also expressed in placenta (15, 16). The form of FR-β 
expressed in normal hematopoietic cells, however, is unable to bind to folate due to aberrant post-
translational modifications (15, 19). The FR-β is also expressed in a functional form in activated 
macrophages associated with most inflammatory diseases (19, 21).
Otherwise, the FR-α and FR-β are selectively expressed in functional forms in several 
carcinomas (15). The FR-β is expressed in approximately 70% of  AML cases and therefore most 
AML cells may be targeted by this receptor (15, 16, 19, 22). Considerations supporting the view 
that FR-β is a potentially valuable target in AML treatment are: the described expression pattern and 
the non-functionality of the receptor form expressed by normal hematopoietic cells, the accessibility 
of the target cells in the bone marrow and peripheral blood and finally the likeliness that engrafting 
leukaemia stem cells carry functional FR-β because of frequent co-expression with CD34 (15, 23). 
Leukaemia stem cells (LSCs) represent a rare population of AML cells capable of endless self-
renewal, proliferation and differentiation into malignant blasts (24). LSCs are an important potential 
target for drug delivery, especially since cytarabine is ineffective against these cells (11). 
FR has advantages as a target for cancer therapy in that the receptor binds tight and 
specifically to FA, a small, presumably non-immunogenic water soluble molecule that can be 
chemically conjugated to drug molecules or nanoparticles without disrupting its binding properties 
(15, 19). FRs in the cell membrane recycle between the cell surface and intracellular compartments, 
internalising receptor-bound folate conjugates by receptor-mediated endocytosis (15, 16, 19). 
Targeted drug delivery effectiveness is limited by FR abundance on the target cell surface 
(19). FR expression in vitro is most often absent in cell lines derived from established FR-
expressing malignant tissues (16). FR expression can be up-regulated in a variety of cells by 
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lowering the extracellular folate concentration (16). FR-β can be up-regulated by treatment with all-
trans retinoic acid (ATRA) and other retinoid nuclear receptor agonists (15, 16, 22, 23). 
Conjugation of FA to liposomes has been successfully conducted and shown increased 
efficacy in FR-expressing cells compared to plain or PEGylated liposomes in several in vitro studies 
(22, 23, 25-29). AML cells have been targeted by PEG-FA-conjugated liposomes, showing 
increased in vitro cytotoxicity compared to PEG-conjugated liposomes and also targeting of AML 
clonogenic cells (LSCs) through the FR-β (22, 23). PEG-FA-conjugated liposomes were also 
demonstrated to prolong animal survival in in vivo studies (23). FA-conjugated liposomes have 
been suggested to be internalised in FR-β expressing AML cells by receptor-mediated endocytosis 
(23).
1.2 Prostate cancer and the PSMA
1.2.1 Prostate cancer: Disease characteristics and treatment strategies
Most prostate cancers are adenocarcinoma, i.e. of prostatic glandular origin, although occasionally 
other forms of cancer can arise within the prostate such as transitional cell and small cell 
carcinomas (30, 31). Both genetic and physiological factors contribute to the development of 
prostate cancer, which contributes to a heterogenic nature of the disease (30). Diagnosis of prostate 
cancer is based on clinical, biochemical, radiological and histological grounds (30). Histopathology 
can provide important prognostic information guiding patient management, most importantly by 
grading the tumour (30). The Gleason system is used to grade prostatic adenocarcinoma based on 
architectural features (30). Prostate cancer is also categorised according to stage using the TNM 
(Tumour, lymph Nodes, Metastasis) system (31).
Prostate cancer is the most commonly diagnosed cancer in American and Norwegian men, 
with approximately 200000 and 4300 new cases in 2009, respectively, and is the second leading 
cause of male cancer death in these countries (32-34). The incidence increases rapidly with age 
(33). Introduction of the test for prostate-specific antigen (PSA) has led to earlier detection of the 
disease, and the serum PSA level and velocity provides prognostic information (14, 31). However, 
concerns have been risen regarding the prevalence of prostate cancer overdiagnosis due to PSA 
screening; assigning diagnosis to men who would not suffer from reduced quantity or quality of life 
if the cancer was never detected (35). The majority of men are now diagnosed with localised disease 
(30, 35, 36). Early prostate cancer is invariably asymptomatic, whereas advanced disease can 
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present with local or distant symptoms such as obstructive lower urinary tract symptoms, 
haematuria or haematospermia, pain, erectile dysfunction, bone pain, pathological fracture, 
anaemia, oedema or hypercalcaemia (30). Metastatic prostate cancer is most commonly located in 
bone (30). A significant number of men diagnosed with prostate cancer will experience relapse, 
requiring surveillance and therapy (36). The focus in this thesis is on advanced prostate cancers.
Prostate cancer has different treatment strategies depending on whether the disease is 
localised or metastatic. Active surveillance is a management option for selected low-risk patients 
(30, 35, 37). Localised early disease is treated with surgical removal of the prostate, i.e. radical 
prostatectomy, radiotherapy (prostate brachytherapy) or high-intensity focused ultrasound (30, 31). 
Radical prostatectomy is also used in selected cases of locally advanced disease (30). Cryotherapy 
is used to treat prostate confined, locally advanced disease and for salvage after failed radiotherapy 
(30). 
Advanced disease is primarily treated with hormonal therapy; relieving symptoms and 
delaying progression (30, 31, 36, 38). Hormonal therapy is also used in earlier stages of the disease, 
adjuvant and neo-adjuvant to radiotherapy (30, 31, 39). Different types of hormonal therapy are 
androgen deprivation therapy (ADT) and treatment with antiandrogens (22). ADT targets testicular 
Leydig cell testosterone production, and can be achieved surgically by castration or medically 
through manipulation of the hypothalamic-pitituary-testicular axis (31, 36, 38). As the disease 
progresses, however, the tumour can become resistant to testosterone depletion with proliferation of 
androgen-independent cells (30, 36, 39). Other hormone manipulations, such as antiandrogens, 
oestrogens and steroids, can be added sequentially at this stage, but the response is often short-lived 
(30, 36). Hormonal therapy is associated with numerous side-effects, including erectile dysfunction, 
reduced libido, hot flushes, osteoporosis, reduced muscle mass, breast swelling and mastalgia, 
weight gain, lethargy, anaemia, mood swings, depression and metabolic complications (30, 36, 38, 
39). 
Patients with castrate-resistant cancers have a generally poor survival (30). Chemotherapy 
with docetaxel is the mainstay treatment for these patients who have metastatic or progressive 
disease, and can improve survival for some (30, 36). Docetaxel is a taxane promoting microtubuli 
polymerisation and inhibiting microtubuli disassembly (27). Zoledronic acid, a bisphosphonate, is 
used for the treatment of bone metastases in patients with castrate-resistant cancers (27). Radiation 
therapy is used for palliation of symptoms from metastatic disease (36).
 A number of new prostate cancer agents are available on the market or undergoing clinical 
trials (36). Three new therapies recently gained FDA approval for castration-resistant prostate 
cancer: sipuleucel-T (Provenge), cabazitaxel (Jevtana) and abiraterone acetate (Zytiga) (40). Other 
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novel prostate cancer drugs are in late-stage developments (40). 
A 1975-2001 annual US report on cancer stated that the 5-year survival rate for prostate 
cancer increased significantly from 70% in the 70s to 99% between 1995 – 2000 (14). Both PSA-
related early detection and improved treatments was believed to have contributed to this decrease in 
mortality (14).
Still, prostate cancer is the leading cause of cancer and the second leading cause of cancer 
death in men, and this warrants the search for new and effective treatment strategies. ADT, the 
mainstay treatment of choice for advanced prostate cancer, has effect for a limited period of time 
and is associated with serious side-effects. Active targeting strategies have the potential of reducing 
side-effects by limiting treatment to cancer cells. The disease-specific prostate-specific membrane 
antigen (PSMA) will be described in the next section as a goal for targeted drug delivery.
1.2.2 The prostate-specific membrane antigen (PSMA): role in prostate cancer and  
targeting strategies for drug delivery
Prostate-specific membrane antigen (PSMA) is a type II membrane glycoprotein that is over-
expressed in all stages of prostate cancer (32, 33, 41-43). The PSMA is expressed in the secretory 
epithelial cells of the normal prostate, and also at lower levels in the spine, brain, peripheral nervous 
system, kidney, striated muscle, small intestine, colon and the salivary gland (33, 43). It is also 
expressed in endothelial cells of the neovasculature in virtually all solid tumours, but not in 
neovasculature associated with normal tissues (33, 43). PSMA expression is suppressed by 
androgens (23). 
PSMA exists in at least three variants due to alternative splicing, but the implication of these 
splice variants in prostate cancer is not known (41). The protein exhibits two unique enzymatic 
functions: NAALADase activity and folate hydrolase activity (33, 41, 42). The folate hydrolase 
activity will be the focus is this thesis. PSMA folate hydrolase activity catalyses cleavage of the 
terminal glutamates from γ-linked poly-glutamates (41, 42). 
PSMA expression in prostate cancer tissues correlates with the stage of the disease, the 
Gleason score, is higher in hormone-refractory cancers and has been shown to be an independent 
marker of disease recurrence (32, 33). As prostate cells become cancerous, more membrane bound 
PSMA is expressed and the folate hydrolase activity is increased (32). The prostate has an 
especially high folate requirement and at physiologically relevant folate levels, it has been shown 
that PSMA offers a growth advantage for prostate cancer cells (32). This can be due to that PSMA 
converts the extracellular poly-γ-glutamated folate to non-glutamated folate that can be taken up by 
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cells (32). PSMA expression has also been shown to significantly increase cellular uptake of folic 
acid under low folate conditions (32). 
PSMA undergoes internalisation constitutively through clathrin-coated pits (32, 41, 43). 
Monoclonal antibody – PSMA complex formation often results in internalisation resembling 
receptor-mediated endocytosis (41). It is proposed that since PSMA internalises folates, it may have 
some transport property for it that is not yet fully understood (32, 41). PSMA could possibly bind 
and transport folates into the cell, potentially implicating it as a novel folate receptor (32). PSMA's 
internalisation function and regulation can be exploited in cancer therapeutics, allowing for a 
targeted therapy approach (41). 
PSMA represents an excellent target for prostate cancer imaging and therapy, being a cell 
surface protein expressed in thousand-fold greater levels in cancer compared to normal tissues (41). 
PSMA is also over-expressed in neovasculature of most solid tumours and plays an important role 
in angiogenesis, making it a possible goal for targeted vasculotoxic therapy of solid cancers as well 
(32, 41, 43). The focus in this thesis is PSMA as a target in prostate cancer therapy. 
PSMA-specific antibodies have been developed for targeted drug delivery; anti-PSMA 
radiotherapy and anti-PSMA immunotoxins (43). Docetaxel-encapsulated aptamer-conjugated 
nanoparticles have been developed that bind to and are taken up by PSMA-expressing LNCaP cells 
(25). Also, bispecific antibodies re-targeting immune cells to PSMA-expressing cells and PSMA 
vaccines have been developed, utilising PSMA as a target for cancer therapy (43).
Targeting PSMA for drug delivery may be particularly useful in metastatic prostate cancer, 
where new and targeted approaches are needed to improve survival.
1.3 Nanocarriers
Drug delivery systems are developed for three main reasons: protecting the drug against 
inactivation, protecting healthy tissues from the drug and favourably changing and controlling drug 
pharmacokinetics (44). In this section, nanocarriers in general and liposomes especially are 
described as drug delivery systems for anticancer therapeutics.
1.3.1 Nanomedicine: Background information and advantages of the use of drug  
delivery nanosystems in cancer therapy
Nanotechnology concerns the study of man-made devices that are in the 1-1000 nm range in at least 
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one dimension (45). Pharmaceutical nanotechnologies are usually defined as nanomedicine (44).
Nanoparticles are engineered and constructed systems in the nanometer size range that can 
be used as vehicles for drug delivery (46). Examples of nanoparticles for drug delivery – also called 
nanocarriers – are dendrimers, micelles, polymeric nanoparticles, nanocapsules, fullerenes, 
nanotubes and liposomes (46, 47). Liposomes are described in section 1.3.2. 
Nanocarriers possess the advantages of high drug-loading capacity and prolonged 
circulation times (47). The encapsulated drug is protected from degradation, and at the same time 
side effects can be reduced by focused delivery of the drug (45, 48). Limitations of the drug can 
also be addressed by use of nanocarriers, including poor aqueous solubility, low bioavailabilty and 
unfavourable pharmacokinetic properties such as rapid elimination by the kidneys (47).
Delivery of anticancer therapeutics from nanoparticles can be categorised as passive or 
active (46, 47). Passive targeting refers to selective transport through tumour vasculature and 
subsequent retention of the nanoparticles (46, 47). This effect rises from abnormality of tumour 
vessels; tumour endothelial cells have gaps in between them ranging from 100 to 780 nm that 
allows nanoparticles to extravasate into the tumour (46). In comparison, normal vessels have tight 
endothelial junctions typically of a 5 to 10 nm size (46). Also, tumours lack effective lymphatic 
drainage that can cause extended retention times for the nanoparticles (46, 49). This is termed the 
enhanced permeability and retention (EPR) effect (46, 49). 
Active targeting refers to drug delivery based on molecular interactions between the 
nanoparticle and the target cell, providing enhanced selectivity (44-46). Examples of commonly 
used receptor targets for nanocarriers are the folate receptor (FR), the vascular endothelial growth 
factor (VEGF) receptor, the transferrin receptor and the CD20 antigen (47). The targeting ligand, 
which can be an antibody, an engineered protein, an aptamer or a peptide, can be coupled to the 
nanocarrier by physical interaction or chemical conjugation (47). Active targeting strategies may 
trigger receptor-mediated endocytosis, which promotes internalisation of nanocarriers (47). It has 
also shown the potential of suppressing multidrug resistance (MDR) via bypassing P-gp-mediated 
drug efflux (29, 47). 
17
Figure 1.3: Multifunctional nanocarrier. 1: nanocarrier, 2: drugs, 3: sterically protecting polymer  
(PEG), 4: targeting ligand (such as FA), 5: specific receptor (such as FR) targeted with the ligand,  
6: cell membrane. Picture from (50).
Multifunctional nanocarriers are nanoparticles with several integrated properties, such as 
drug or imaging agent delivery, targetability, prolonged circulation, PEGylation (see section 1.3.2) 
and stimuli-sensitivity (44, 47).  
1.3.2 Liposomes as drug delivery vehicles in cancer therapy
Liposomes are vesicles with phospholipid bilayer membrane structures and sizes from 
approximately 50 – 1000 nm in diameter (44, 48, 51). The phospholipids form bilayers in aqueous 
solutions due to their amphipathic nature, thereby lowering the energy of the system (48). The 
resulting lipid membrane has a very low permeability for ions and polar molecules, while water 
molecules traverse quite easily (48). 
Liposomes have a compartmental structure enabling them to function as a storage and drug 
carrier, protecting its contents from degradation (48). Hydrophilic drugs can be encapsulated in the 
aqueous core of liposomes (52). The hydrophobic membrane prevents leakage of hydrophilic 
substances from the aqueous core, and it can also encapsulate hydrophobic drugs (52). Liposomes 
are considered biocompatible and biodegradable due to their lipidic composition (48, 51). 
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Figure 1.4: Liposome structure. Hydrophilic drugs (blue) encapsulated in the aqueous core and 
lipophilic drugs (red) encapsulated in the lipid bilayer. Picture from (53).
To increase the stability of liposomes in a physiological environment, cholesterol can be 
incorporated into the phospholipid bilayer (44, 48). Then the lipids become more densely packed 
and the membrane is rigidified by cholesterol aligning in the hydrophobic core (48). 
Pharmacokinetic properties of liposomes are important parameters, because the drug will 
adopt the pharmacokinetic disposition from its carrier until they are released from it (44, 48). 
Hence, liposomes can change the tissue distribution and the clearance rate of the drug (48). The 
pharmacokinetic behaviour of liposomes depends on physiochemical properties such as size, 
surface charge, membrane lipid packing, steric stabilisation and route of administration (44, 48). A 
liposome size of 80 to 200 nm is considered to give a satisfactory reservoir capacity and at the same 
time having an adequate bioavailability – larger particles are eliminated more rapidly by the 
mononuclear phagocyte system (MPS) (48).
Elimination of liposomes takes place by escape of the drug from circulating liposomes, local 
metabolic elimination in tumour tissues and by the mononuclear phagocyte system (MPS) (48). 
Conventional liposomes and other nanocarriers undergo rapid elimination from the blood by the 
MPS (44, 48). Plasma proteins are absorbed onto the liposomal membrane, causing opsonisation 
and recognition by the cells of the MPS, and finally accumulation in the liver and metabolism by 
specialised Kuppfer cells (48). To slow down the MPS recognition of liposomes, polyethylene 
glycol (PEG) chains can be attached to the membrane surface, creating long-circulating liposomes 
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(44, 54, 55). PEG is a biocompatible, non-toxic and highly soluble polymer that causes very low 
stimulation of the immune system (44, 48). The flexible polymeric chains form a sterically 
protective hydrophilic film over the surface that also improves formulation stability by preventing 
liposomes from aggregating (44, 48). Liposomes have a tendency to aggregate and fuse if the 
resultant of electrostatic interactions, steric properties and hydration forces allow it (48). Compared 
to conventional liposomes, PEGylated liposomes have a longer half-life, an improved tissue 
distribution by avoiding accumulation in healthy tissues, low systemic plasma clearance, low 
volume of distribution and greater Area Under Curve (AUC) values (48). Sometimes however, 
PEGylated liposomes can experience difficulty in releasing the drug and killing tumour cells (51).
The drug can be delivered from liposomes to target cells by one or several of the following 
mechanisms: absorption of liposomes on the cell membrane, fusion of liposomes with the cell 
membrane, receptor-mediated endocytosis (particle size <150 nm in diameter) or transfer of the 
drug from the liposomes to plasma lipoproteins (48). Receptor-mediated endocytosis by ligand 
attachment of liposomes increases intracellular drug levels, but the endocytosed material is 
subjected to lysosomal degradation, which can result in reduced biological activity (51).
In summary, liposomes serve as an attractive drug delivery system for anticancer drugs due 
to increasing drug solubility, elongation of circulation times and focused delivery of the drug (48). 
Passive and active targeting strategies can be applied to liposomes, as described in section 1.3.1. 
Folic acid (FA) can be conjugated to liposomes and as a targeting ligand it has advantages of simple 
conjugation chemistry, non-immunogenicity and low cost (47). FA-conjugated liposomes have been 
shown to facilitate cancer-specific drug delivery (47).
By encapsulation in liposomes, the therapeutic index of the drug is improved and multidrug 
resistance can be bypassed (48). Liposomes are well tolerated and have a similar structure to 
biological membranes that makes them less likely to be accumulated in the body over long time, 
which is a concern for many other nanocarriers (48). 
Liposomes were first discovered in 1961, and today several liposomal formulations are 
available in the market or undergoing clinical trials (44, 48). Examples of liposomal formulations in 
clinical use today are Caelyx® (PEGylated liposomal doxorubicin), DaunoXome® (liposomal 
daunorubicin) and Myocet® (liposomal doxorubicin) (44, 46). 
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1.4 Daunorubicin (DNR) and emetin (EME): choice of drugs for encapsulation in 
multifunctional liposomes
Anthracyclines, with doxorubicin (DOX) and daunorubicin (DNR) first isolated from Streptomyces  
peucetius in the 1960s, remain among the most effective anticancer drugs developed (56). The 
anticancer mechanism of action of anthracyclines is still a controversial matter, and the mode of 
action seems to be concentration-dependent (56). The following mechanisms have been suggested: 
DNA intercalation, generation of free radicals causing DNA damage or lipid peroxidation, DNA 
binding and alkylation, cross-linking of DNA, interference with DNA unwinding/strand separation 
and helicase activity, direct membrane effects and topoisomerase II inhibition initiating DNA 
damage or inducing apoptosis (56). 
DNR has activity against AML, and has been used as a part of standard AML treatment for 
several decades (11, 56). However, the clinical use of DNR faces serious challenges such as 
resistance development in cancer cells and toxicity in healthy tissues (56). Anthracycline treatment 
is most notably associated with a dose-dependent cardiotoxicity in the form of chronic 
cardiomyopathy and congestive heart failure (56). Tumour-targeted nanocarriers have been 
developed for improving the efficacy and cardiac safety of currently approved anthracyclines (56-
58). 
Figure 1.5: Chemical structure of DNR and EME. Picture of DNR from (56) to the left, picture of  
EME from (59) to the right.
On the basis of the work performed by Gausdal et al. (60), it was decided to investigate a 
potential synergism between DNR and a protein synthesis inhibitor. Gausdal et al. demonstrated a 
synergistic effect of cycloheximide (CHX) and DNR in several AML cell lines in vitro and also in 
in vivo experiments (60). In this thesis, emetin (EME) was chosen as protein synthesis inhibitor on 
the basis of its isoelectric point, which is quite similar to that of DNR (Figure 1.6). Also, unlike 
CHX, EME has approval for use in humans (61) and has been studied in both animals and humans 
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and therefore has a shorter way towards regulatory approval (62, 63). Hence, EME offers a shorter 
way towards clinical use compared to CHX, and it is more likely that EME treatment can be 
approved. A potential synergism of DNR and EME offers possibilities for improved therapeutic 
outcome in AML, a highly fatal malignancy. The drugs were to be combined in a single, 
multifunctional PEG-FA-conjugated liposome, reducing drug toxicity and targeting cancer cells 
specifically.
Figure 1.6: Charge - pH relationship of EME and DOX (unpublished data from Lars Herfindal).  
The isoelectric point for DOX and DNR is identical, pH 9.1 (Herfindal, 2011, unpublished data).  
The isoelectric point of the drugs is exploited in the acid precipitation method drug loading of  
liposomes, as described in section 3.5.1.
EME is an alkaloid, found in Psychotria ipecacuanha (59, 64). The earliest use of ipecac in 
traditional medicine was as an emetic and expectorant (59). EME has been used extensively as an 
antiparasitic drug against amoebiasis and amoebic dysentry caused by Entamoeba histolytica, but 
its use was discouraged due to excessive toxicity (59, 64). EME is a protein, DNA and RNA 
synthesis inhibitor, and it has antiviral and anticancer activities (59). It has proved to exhibit 
cytotoxity in several cancer cell lines, including different leukaemia cell lines, and the cytotoxic 
mechanism is considered to be caused by protein synthesis inhibition and DNA interaction (59). 
Recently, it has been shown that EME is a substrate of P-gp, offering a potential use of overcoming 
multidrug resistance in cancer therapy (59, 65). Studies have been performed combining EME with 
other therapeutic agents in cancer drug discovery research (59). An additive effect was observed 
when EME was combined with doxorubicin in human neuroendocrine tumour cell lines (65). EME 
was combined with cisplatin in a leukaemia cell line (Jurkat T-cells) in vitro, enhancing apoptosis in 
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an additive but synergistic fashion, and also showing that emetine itself was a powerful inducer of 
apoptosis in leukaemia cells (64). The medical use of EME has been discouraged due to its toxicity, 
and chronic usage has been associated with myopathy and cardiotoxicity (59). 
1.5 Aim of study
The aim of this study was to synthesise FA-conjugated and PEGylated liposomes for investigation 
of targeted drug delivery to FA-expressing AML cell lines and PSMA-expressing prostate cancer 
cell lines. PEGylated (PEG-conjugated) liposomes were synthesised to compare the effect of 
targeted and non-targeted liposomes. PEGylated and FA-conjugated (PEG-FA-conjugated) 
liposomes have previously been shown to give an increased anticancer efficacy in FA-expressing 
cell lines compared to PEG-conjugated liposomes (22, 23, 25, 26).
The liposomes were made using hydrogenated egg phosphatidylcholine and cholesterol to 
create a reinforced lipid bilayer with a relatively high lipid transition temperature (60°C) to improve 
physiological stability. DSPE-PEG was incorporated to slow down MPS recognition of liposomes 
and finally, DSPE-PEG-FA was incorporated to target liposomes to FR on AML cells, or to prostate 
cancer cells expressing PSMA. DNR and EME were chosen as drugs for incorporation in the 
liposomes, as described in section 1.4. 
The main focus in this thesis was on AML, with MOLM-13 as the cell line of investigation. 
We wanted to validate the expression of FR-β in this cell line, and to see if it indeed could be used 
as a target for drug delivery by FA-conjugated multifunctional liposomes. As mentioned in section 
1.1.1, AML remains a highly fatal malignancy and there is a need for developing more effective 
therapeutics. Liposomal targeted drug delivery via FR offers a possibility of improving therapeutic 
outcomes, reducing mortality and reducing side-effects. Combining DNR and EME in a single 
multifunctional liposome would offer a new approach in the treatment of AML, and the synergistic 
effect of these drugs was to be investigated.
On the basis of promising results using multifunctional liposomes in the PSMA-expressing 
prostate cancer cell line LNCaP (41), obtained by Herfindal in 2011 (unpublished data), it was 
decided to perform experiments in this cell line as well. PSMA represents a target for drug delivery, 
and we wanted to investigate if its function as a folate hydrolase could be exploited by FA-
conjugated liposomes. The LNCaP cell line is p53 positive, and the PC-3 prostate cancer cell line 
was included due to its status as p53 deficient (66) to investigate a potential synergism between 
DNR and EME. p53 deficient cells have been shown to be particularly sensitive towards the 
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combination of DNR and a protein synthesis inhibitor (unpublished data, Gausdal) (60). The PC-3 
cell line was to be transiently transfected with PSMA to investigate if this expression led to higher 
efficacy of the FA-conjugated liposomes. DNR and EME were used as the liposomal drugs in these 
cell lines as well, offering a potentially new treatment for prostate cancer. The synergistic effect of 
DNR and EME was investigated in these cell lines as well. 
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2. Materials
2.1 Cell lines
Cell line ATCC® number Supplier
HEK293 CRL-1573 American Type Culture Collection 
(ATCC)
LNCaP CRL-1740 American Type Culture Collection 
(ATCC)
MOLM-13 (wt original) Supplied by prof. Bjørn Tore Gjertsen, 
Univ. Bergen
Origin of the cell line described by (9).
MOLM-13 SH p53 
(silenced p53)
Produced at TSG, Univ. Bergen
MV4-11 CRL-9591 American Type Culture Collection 
(ATCC)
NRK CRL-1570 American Type Culture Collection 
(ATCC)
PC-3 CRL-1435 American Type Culture Collection 
(ATCC)
2.2 Materials used in cell culture
Material Catalogue number Supplier
BisBenzimide H33342 
trihydrochloride (Hoechst)
B2261-100MG Sigma-Aldrich
Cell proliferation Reagent 
WST-1
11644807001 Roche
Dulbecco's modified eagles 
medium 10x without folic acid 
with L-glutamine and  NaHCO3
D2429 Sigma-Aldrich
Dulbecco's Modified Eagle's 
Medium
with glucose/L, L-glutamine, 
NaHCO3, pyridoxine HCl
D5796 Sigma-Aldrich
Fetal bovine serum (FBS)
Standard quality
A15-101 PAA Laboratories GmbH 
Iscove's Modified Dulbecco's 
Medium
I3390 Sigma-Aldrich
Penicillin-Streptomycin P0781-100ML Sigma-Aldrich
Plasmids:
PSMA-encoding DNA plasmids
GFP-encoding DNA plasmids
Supplied by prof. Dean Bacich, 
Univ. Pittsburgh (PSMA) and 
prof. James Lorens, Univ. 
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Empty vector DNA plasmids Bergen
RPMI-1640 medium 
with L-glutamine and NaHCO3
R8758 Sigma-Aldrich
Trypsin 1:250 T-0646 Sigma-Aldrich
2.3 Liposome materials
Material Catalogue number Supplier
Cholesterol C8667-5G Sigma-Aldrich
DSPE-PEG-FA (1,2-disteraoyl-
sn-glycero-3-
phosphoetanolamine-N-
((polyethylene glycol-
5000)folate) (ammonium salt)
(Reconstituted in 5 ml ethanol)
880123P Avanti® Polar Lipids
Hydrogenated Egg Phosphatidyl 
Choline (HEPC)
E PC-3 Lipoid
DSPE-PEG (1,2-Disteraoyl-sn-
glycero-3-Phosphoetanolamine-
N-[Methoxy(Polyethylene 
glycol)-2000]) (ammonium salt)
880120P Avanti® Polar Lipids
Texas Red® DHPE (Texas Red® 
1,2 Dihexadecanoyl-sn-Glycero-
3-Phosphoethanolamine, Triethyl 
ammonium salt)
T1395MP Invitrogen
2.4 Drugs
Material Catalogue number Supplier
Cerubidin® 20 mg, 
daunorubicin
(Reconstituted in 5 ml milli Q 
water)
01 74 59 Sanofi Aventis
Emetine dihydrochloride 
hydrate
E-2375 Sigma-Aldrich
2.5 Antibodies
Material Catalogue number Supplier
Anti-beta actin antibody [AC-
15]
ab6276 Abcam
Anti-FOLR2,
500 μg/mL
ab56067 Abcam
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Anti-mouse IgG (whole 
molecule) alkaline phosphatase 
produced in goat
A3562-.5ML Sigma-Aldrich
Anti-PSMA (C-terminal) 
polyclonal antibody,
0,25 mg/ml
AB10614 Millipore
Anti-rabbit IgG (whole 
molecule) alkaline phosphatase 
conjugate antibody developed 
in goat
A-3687 Sigma-Aldrich
2.6 Phosphatidylcholine Assay Kit ingredients
The Phosphatidylcholine Assay Kit, catalogue number 10009926, was provided by Cayman 
Chemical Company.
PC buffer, 30 ml
3 ml PC buffer concentrate, cat.no 10010066, final buffer of
   50 mM Tris-HCl, pH 8.0
   0.66 mM CaCl2
27 ml milli Q water
PC colour detector, 3 ml
PC colour detector, cat.no 10010067, lyophilised powder of
   DAOS (N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline)
   4-aminoantipyrine
3 ml PC buffer
PC enzyme mixture, 1 ml
PC enzyme mixture, cat.no 10010068, lyophilised powder of
   choline oxidase
   horseradish peroxidase
1 ml PC buffer
PC-specific PLD, cat.no 10010069, containing a solution of
phosphatidylcholine-specific phospholipase D
Phosphatidylcholine Standard, 1 ml
Phosphatidylcholine Standard, cat.no 10010070, lyophilised powder of
   phosphatidylcholine
1 ml detergent solution
Phosphatidylcholine Stock Standard 200 mg/dl, 1.5 ml
200 μl Phosphatidylcholine Standard
1.3 ml detergent solution
PC detergent solution, cat.no 10010071, containing a solution of
triton X-100
2.7 Reagents and chemicals
Material Catalogue number Supplier
30% Acrylamide/Bis solution 151-0158 Bio-Rad Laboratories
Ammonium persulfate (APS) 161-0700 BioRad
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Ammonium sulphate 1.01217.1000 Merck
Bromophenol blue (BFB) 80-1129-15 Pharmacia
Calcium chloride dihydrate 
(CaCl2·2H2O)
2382 Merck
CDP-star® MSC100 Tropix
Chloroform (CHCl3) 2447 Merck
Chloroquine C-6628 Sigma-Aldrich
Complete Mini 11836153001 Roche
Deoxycholic acid (NaDOC) D-2510 Sigma-Aldrich
Diethanolamine (DEA) D8885-500G Sigma-Aldrich
Dimethyl sulphoxide (DMSO) D2650 Sigma-Aldrich
1,4 Dithioerythritol (DTE) 1.24511.0025 Merck
Ethanol absolute 32221-2,5L Sigma-Aldrich
Ethylene dinitril tetraacetic acid 
(EDTA) disodium salt dihydrate
1.12029.1000 Merck
Formaldehyde solution min. 
37%
1.04003 Merck
D (+) Glucose 24371.264 VWR International
L-Glutamine, non-animal 
source
G8540-100G Sigma-Aldrich
Glycerol about 80% 1.04094.1000 Merck
Glycine (C2H5NO2) 8.16013.1000 Merck
Hepes sodium salt H7006 Sigma-Aldrich
I-block TM A1300 Tropix
Isobutanol 1.00984.1000 Merck
LipofectamineTM 2000 11668-027 Invitrogen
Magnesium chloride 
hexahydrate (MgCl2·6H2O)
31413 Sigma-Aldrich
Methanol (CH4O) 24229-2.5L-R Sigma-Aldrich
Nitro-Block II TM T2184 Applied Biosystems
Nitrogen (N2)  for lipid 
extrusion
7727-37-9 Yara
Nonidet P-40 (NP-40) 74385 Fluka
Phenol Red solution 0.5% in 
DPBS
P-0290 Sigma-Aldrich
Potassium Chloride (KCl) 1.04936.1000 Merck KGaA
Potassium dihydrogen 
phosphate (KH2PO4)
1.04873.1000 Merck
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Precision Plus Protein® All Blue 
Standards
161-0373 BioRad
Protein Assay Dye Reagent 
Concentrate
500-0006 BioRad Laboratories
Protein standard II 
Bovine Serum Albumin (BSA)
500-007 BioRad
Re-Blot Plus Strong Solution 
10x
2504 Millipore
Sephadex TM G-25 Medium 17-0033-01 Amersham Biosciences
Sodium azide (NaN3) S8032-25G Sigma-Aldrich
Sodium chloride (NaCl) 1.06404.1000 Merck
Sodium dodecyl sulphate (SDS) L5750-500G Sigma-Aldrich
Sodium hydrogen carbonate 
(NaHCO3)
1.06329.1000 Merck
di-Sodium hydrogen phosphate 
dihydrate (Na2HPO4·2H2O)
1.06580.1000 Merck
Sucrose 1.7660-3 BDH AnalaR Kebo Lab AB
N, N, N', N'-
Tetramethylethylenediamine
(TEMED)
T9281 Sigma-Aldrich
Tris (hydroxymethyl) - 
aminomethane
1.08382.2500 Merck KGaA
Tween® 20 P5927-500ML Sigma-Aldrich
2.8 Technical equipment and instruments
Name Supplier
Cary quarts cuvette Starna®
Cell counting chamber 0.100 mm depth Bürker
Econo-Columns®: 1.5x15 cm and 0.7x10 cm BioRad
LIPEXTM extruder Northern Lipids
Pellet pestle® homogeniser Kontes
SDS-PAGE gel electrophoresis and Western 
blotting equipment
BioRad
Instruments:
Axiovert 200M Fluorescence/Live cell imaging 
microscope
Zeiss
Balances Mettler Toledo
C6 flow cytometer Accuri®
CKX31 microscope Olympus
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Electrophoresis power supply EPS 301 Amersham pharmacia biotech
HAAKE C10-K10 Heating circulator Thermo electron corporation
Holten Lamin Air Safety bench/Lab hood 
(vevskultur)
Holten
Labofuge 400 centrifuge Heraeus
LAS 3000 imager Fujifilm
Locator 8 plus Cryo Biological storage system Thermolyne®
Membrane vacuum pump MZ 2C Vacuubrand
Microcentrifuge Biofuge Fresco Heraeus
Milli-Q® integral water purification system:
For the making of Milli Q (MQ) water
Millipore
Mini Centrifuge Costar®
MS2 Minishaker IKA® 
Peristaltic pump XX80 202 30 Millipore
RCT basic magnetic stirrer hotplate IKA Labortechnik
Rotary Evaporator Laborota 4000 Heidolph instruments
Steri – Cycle CO2 Incubator Thermo Forma
Swip shaker Edmund Bühler
UVM 340 microplate spectrophotometer ASYS
UV-visible spectrophotometer Varian Cary
Vario Vacuum pump Vacuubrand
Zetasizer Nanoseries Nano-ZS Malvern Instruments Nordic
2.9 Computer software
Name Supplier
AxioVision Carl Zeiss
Cary Win UV Agilent Technologies
DigiRead Asys
FlowJo TreeStar
Image Reader LAS-3000 FUJIFILM
ScanPlus Asys
Zetasizer software Malvern
2.10 Solutions, buffers, media
Cell culturing:
RPMI-1640 cell medium with L-glutamine and NaHCO3
500 ml RPMI-1640 added 50 ml FBS and 5 ml Penicillin/Streptomycin (final 100 IU/ml penicillin 
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and 100 μg/ml streptomycin)
Dulbecco's Modified Eagle's Medium (DMEM)
500 ml Dulbecco's Modified Eagles Medium added 50 ml FBS and 5 ml Penicillin/Streptomycin 
(final 100 IU/ml penicillin and 100 μg/ml streptomycin)
Dulbecco's Modified Eagles Medium (DMEM) without folic acid
50 ml Dulbecco's Modified Eagles Medium 10x added 450 ml milli Q water, 0.15 g L-glutamine, 
1.0 g sodium bicarbonate NaHCO3, sterile filtered at 0.2 μm then added 50 ml FBS and 5 ml 
Penicillin/Streptomycin (final 100 IU/ml penicillin and 100 μg/ml streptomycin)
Iscove's Modified Dulbecco's Medium (IMDM)
500 ml Iscove's Modified Dulbecco's Medium added 50 ml FBS and 5 ml Penicillin/Streptomycin 
(final 100 IU/ml penicillin and 100 μg/ml streptomycin)
1xPhosphate Buffered Saline (PBS), 500 ml
0.1 g KCl, 0.1 g KH2PO4, 0.675 g Na2HPO4·2H2O, 4 g NaCl and 450 ml milli Q water. pH 
adjusted to 7.4 using 1M NaOH, volume adjusted to 500 ml and the solution was autoclaved 
Trypsin-EDTA, 200 mL
40 mg EDTA disodium salt, 200 mg Glucose, 80 mg KCl, 1600 mg NaCl, 0.4 mg Phenol red 
solution, 116 mg NaHCO3, 100 mg trypsin. Milli Q water added to a total of 200 mL. The solution 
was sterile filtered.
2xHEPES buffer for transfection 500 ml
8.0 g NaCl, 6.5 g Hepes sodium salt and 5.25 g Na2HPO4 dissolved in 500 ml milli Q water.
pH adjusted to 7
4% FIX solution, 500 ml
54 ml Formaldehyde solution 37%, 446 ml PBS. pH adjusted to 7.4 by NaOH or HCl
FIX solution with DNR 0.1  μ  g/ml   50 ml 
50 ml 4% FIX solution added 10 μl Cerubidin® daunorubicin 5 mg/ml
Western blotting:
RIPA buffer with Complete, 100 ml
1 ml NP-40, 0.5 ml SDS 10%, 0.5 g Na DOC, 0.606 g Tris, 0.876 g NaCl, 2 Complete Mini 
tablets. Milli Q water added to a total volume of 100 ml.
20% SDS, 1 l
200 g SDS, milli Q water added to a total volume of 1 l
0.5 M Tris-HCl, 500 ml
30.29 g Tris. Water added to a total volume of 500 ml and the pH of the solution adjusted to 6.8 
using HCl
1.0 M Tris-HCl, 1 l
121.14 g Tris. Water added to a total volume of 1 l and the pH of the solution adjusted to 8.7 using 
HCl
5xSDS sample buffer, 1ml
6.25 ml 20% SDS, 14.35 ml Glycerol. Bromophenol blue added until the solution was blue, then 
added 965 mg DTE and 3.0 ml 0.5 M Tris-HCl pH ~ 6.8. Milli Q water added to a total volume of 
1 ml
5x Running buffer, 5 l
151.2 g Tris, 720 g Glycine, 125 ml 20% SDS. Water added to a total volume of 5 l
10xBlotting buffer, 1 1
30.0 g Tris, 144.0 g Glycine. Milli Q water added to a total volume of 1 l. 
Blotting buffer, 2000 ml
200 ml 10xBlotting buffer added 300 ml Methanol and 1500 ml milli Q water
PBS Tween, 5l
5 l 1xPBS added 10 ml Tween 20 and 5 g MgCl2
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WB 2 – blocking buffer
1 l 1xPBS added 2 g I-Block. The solution was heated to 70 °C using a magnet stirrer, then cooled 
to room temperature. Next it was added 1 ml Tween, 1 g MgCl2 and 1 ml Sodium Azid NaN3 20% 
solution
1xDiethanolamine (DEA) buffer reagent, 100 ml
1.1 ml Diethanolamine added some milli Q water was added to dissolve the DEA. pH was adjusted 
to 9.5 with concentrated HCl. Next it was added 0.02 g MgCl2 and milli Q water to a total volume 
of 100 ml
Substrate solution
45 ml 1xDEA added 225 μl CDP-star and 450 μl Nitro-Block 
Liposomes:
250 mM ammonium sulphate pH  5.5, 100 ml  
3.3035 g ammonium sulphate added 100 ml milli Q water. pH was adjusted to 5.5 by 25% NH4+ 
5% sucrose solution, 50 ml
2.5 g sucrose added 50 ml milli Q water
2.11 Disposable equipment and consumables
Name Supplier
15 and 50 mL sterile PP-tubes Cellstar® Greiner Bio-One
Amersham HybondTM-P GE Healthcare
Aspirations – pipette 2 mL Sarstedt
Disposable cuvettes 1.5 ml, cat number: 7590 
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Brand
Easy flask 25 and 75 V/C Nunc TM
Filtropur L 0.2 μm pressure filtration units Sarstedt
Glass beads 0.45 mm Biospec Products 
Microtubes 1.5 mL MCT-150-C Genuine Axygen Quality
Nucleopore® track-etch membranes (25 mm 
diameter) for lipid extrusion. Pore sizes: 0.8 μm, 
0.4 μm, 0.2 μm and 0.1 μm
Whatman®
Nunc® CryoTube 1.8 ml Thermo Fisher Scientific
Pipette tips 1000, 200, 100 and 10 μL Gilson
Pipette tips 1000, 200, 100 and 10 μL Corning
Serological pipettes 10 and 5 ml VWR
Single-use Insulin syringe OmniCan® 50 Braun
Syringes 1 ml, 3 ml, 5 ml BD Medical
Tissue culture dishes:
Nunclon surface Multidish 6-wells, 12-wells, 
48-wells and 96-wells
Nunc TM
Transfer pipettes 3.5 ml and 2 ml Sarstedt
Zetasizer nanoseries folded capillary cells Malvern
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3. Methods
3.1 Cell culturing
All cell culturing and other work with cell lines was performed in a sterile environment, using a 
Holten Laminar Air Flow (LAF) safety bench.  All cell lines were examined in an Olympus CKX31 
microscope on a regular basis, ensuring healthy cells free of bacterial contamination. Cell media 
were supplemented with 100 IU/ml penicillin and 100 μg/ml streptomycin to avoid bacterial growth 
and 10% foetal bovine serum (FBS) unless otherwise specified. Centrifugation of cells was 
performed at 160 x g in a Heraeus Labofuge 400 centrifuge or a Costar® Mini centrifuge. The cells 
were cultured in a humidified Steri – Cycle CO2 Incubator at 37°C, 6% CO2. 
3.1.1 Culturing of suspension cells: MOLM-13 and MV4-11 cell lines
The MOLM-13 wt and the MOLM-13 SH p53 (silenced p53) cell line were cultured in Dulbecco's 
Modified Eagle's Medium (DMEM) without FA because culturing of FR-expressing cells in FA-free 
medium is shown to enhance the expression of FR (16, 67, 68). Both cell lines were cultured in FA-
free DMEM without any negative effects on the cells for 3 – 4 weeks. To prevent a negative effect 
from either FA depletion or DMEM medium, the cells were replaced with cells from backup cell 
lines cultured in RPMI-1640 medium after this period of time. For the preparation of cell lysates for 
Western blotting, the MOLM-13 cell lines were also cultured in RPMI-1640 medium.
The MV4-11 cell line was cultured in DMEM without FA in order to enhance the expression 
of the FR (67, 68). Culturing in this medium was without negative adverse effects for 2 – 3 weeks. 
Like previously described for the MOLM-13 cell lines, the cells were replaced with cells from 
backup cell lines cultured in Iscove's Modified Dulbecco's Medium (IMDM) after this period of 
time. IMDM is the preferred culturing medium for this cell line and it was difficult to culture the 
cells in other media; negative effects were visible after a period of time in terms of a high 
proportion of cell death.
All suspension cell lines were cultured in FA-free DMEM medium in dilution series in a 12-
well tissue culture dish. New dilution series were made every week.
To expand suspension cells for experiments or Western blotting, the cells were cultured in 
10-ml medium NuncTM easy flasks. Cells were allowed to condition in FA-free medium for at least 4 
days prior to experiments. The cells were kept at a concentration between 0.4·105 and 8·105 
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cells/ml, and dilution was done by removing cell suspension and adding fresh medium. Cell number 
was estimated with a Bürker cell counting chamber. 
3.1.2 Culturing of adherent cells: PC-3, LNCaP and NRK cell lines
The PC-3 cell line was cultured in RPMI-1640 medium. The cells were cultured in 10-ml or 20-ml 
medium NuncTM easy flasks, where the medium was monitored by visual inspection on a regular 
basis and replaced when it had a yellow colour. When the cells had reached 70 – 90% confluence, 
they were detached as described in section 3.1.3 and reseeded in a new flask at a minimum of 10% 
confluence or in a tissue culture dish. Cells were detached and reseeded or medium was changed at 
least three times per week.
The LNCaP cell line was cultured in RPMI-1640 medium. The cells were cultured in 10-ml 
or 20-ml medium NuncTM easy flasks, and the medium was replaced regularly as described for the 
PC-3 cell line. When the cells had reached 70 – 90% confluence, they were detached by flushing 5 
– 8 ml PBS (see Table 2.10 for content) at room temperature repeatedly using a pipette. Next, the 
cells were centrifuged for 4 min, re-suspended in fresh medium and reseeded in a new flask at a 
minimum of 15% confluence or in a tissue culture dish. Cells were detached and reseeded or 
medium was changed at least 2 times per week.
The NRK cell line was cultured in 10-ml NuncTM easy flasks in DMEM medium. When the 
cells had reached 70 – 90% confluence, they were detached as described in section 3.1.3. Reseeding 
in a new flask was performed at a minimum of 10% confluence. 
All adherent cell lines were cultured until a maximum of 15 generations in total. After this 
they were replaced with newly defrosted cells. 
3.1.3 Protocol for trypsin-aided detachment of adherent cells
Medium was removed and the cells were rinsed with PBS at room temperature. Next, PBS and 
trypsin-EDTA (see Table 2.10 for content) were added in a 1:2 relationship and the cells were 
incubated at 37°C, 6% CO2 until the cells had detached from the flask, i.e. would move when 
examined in the light microscope. Trypsin was inactivated by adding an equal volume of fresh 
medium to the PBS/trypsin-EDTA/cell mixture, and the cell suspension was centrifuged for 4 min. 
The cell pellet was re-suspended in fresh medium and reseeded as described in section 3.1.2.
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3.1.4 Freezing and defrosting of cells from liquid nitrogen
Freezing: The cell suspension was centrifuged for 4 min and re-suspended in fresh medium 
to a concentration of 7 – 10·106 cells/ml. 500 μl FCS with 20% DMSO was added to 500 μl cell 
suspension, mixed gently and transferred to a sterile 1.8 ml NuncTM cryo tube. The tube was 
wrapped in tissue paper and put in a Styrofoam box to ensure slow freezing. The box was frozen at 
-80ºC for 24 – 48 h before transferring the NuncTM cryo tubes to liquid nitrogen. 
Defrosting  :  Defrosting of cells was performed as rapid as possible to avoid cellular damage 
and death. First, the NuncTM cryo tube was removed from the liquid nitrogen and wrapped in paper 
to keep it frozen until installed in the LAF hood. The tube was opened slightly, allowing controlled 
pressure release and next thawed quickly by holding it in the hand. When the frozen contents had 
loosened from the tube, it was transferred to a sterile 15 ml tube. 10 ml pre-heated medium at 37ºC 
was poured drop-wise over the frozen cells. Finally, the cell suspension was transferred to one or 
two 10-ml flasks and the medium was changed the next day to remove DMSO. 
3.2 SDS-PAGE and Western blotting
The contents of all solutions and buffers used for SDS-PAGE and Western blotting are described in 
Table 2.10.
3.2.1     Preparation of cell lysates for SDS-PAGE and Western blotting
The cell suspension was centrifuged for 5 min and the resulting pellet re-suspended in 10 ml cold 
PBS. The suspension was re-pelleted by another 5 min centrifugation, and next re-suspended in 1 
ml cold PBS. The suspension was centrifuged for 4 min and the PBS carefully removed from the 
pellet. Finally, the pellet was re-suspended in 50 – 100 μl cold RIPA buffer with Complete to lyse 
the cells and frozen at -80°C. The cell lysates were kept cold during preparation and stored cold to 
avoid degradation of the proteins.
3.2.2     Protocol for protein measurement
The cell lysates were thawed on ice and the pellets re-suspended using a homogeniser (Kontes 
Pellet pestle®). Next the samples were centrifuged at 9450 x g in a Heraeus Microcentrifuge 
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Biofuge Fresco for 20 min at 4°C, and the supernatant containing proteins collected and stored on 
ice. Solutions for a protein standard curve were made using ingredients in amounts described in 
Table 3.1. The samples were diluted in MQ water to a total volume of 50 μl. 3 ml Bio-Rad Protein 
Assay Dye Reagent Concentrate was diluted in 12 ml water, the solution was filtered and 750 μl of 
this solution was added to each of the tubes for the standard curve and the samples. Two parallels of 
280 μl for each solution were added to a 96-well Nunclon multidish and the absorbance of the 
solutions at 595 nm was determined using an ASYS UVM 340 microplate spectrophotometer. The 
software KIMpro was used to control the instrument and analyse measurements. A standard curve 
was calculated by the software and the protein concentration in the samples determined based upon 
this. 
Table 3.1: Solutions for the making of a protein standard curve.
Concentration, mg/ml BSA 1 mg/ml volume, μl Water volume, μl
0.8 40 10
0.6 30 20
0.4 20 30
0.2 10 40
0.1# 10 90
0.05# 10 190
0 0 50
# of these solutions 50 μl was pipetted into a new tube and this was used in further analysis.
3.2.3 Protocol for SDS-PAGE
A 12.5% acrylamide separation gel was made by mixing the ingredients described in Table 3.2, with 
10% APS and TEMED added as the last ingredients to start the polymerisation. The gel solution 
was applied between the plates up to 3 cm below the top, isobutanol was applied to even out the 
surface and the gel was left to solidify for 20 – 30 min. The isobutanol was removed from the 
solidified gel and a 5.4% acrylamide stacking gel was made in a similar way using the ingredients 
described in Table 3.3. The stacking gel solution was applied on top of the separation gel and left to 
solidify for 20 – 30 min.
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Table 3.2: 12.5% acrylamide separation gel ingredients
Ingredient Amount for the making of 2 gels
30% Acrylamide/Bis 6.3 ml
1 M TrisHCl pH 8.7 5.7 ml
Milli Q water 2.7 ml
20% SDS 152 μl
10% APS 135.2 μl
TEMED 13.6 μl
Table 3.3: 5.4% acrylamide stacking gel ingredients
Ingredient Amount for the making of 2 gels
30% Acrylamide/Bis 1.36 ml
0.5 M TrisHCl pH 6.8 2 ml
Milli Q water 4.1 ml
20% SDS 40 μl
10% APS 40 μl x 2 = 80 μl
TEMED 5.25 μl x 2 = 10.5 μl
Samples with determined protein content (see section 3.2.2) were prepared for loading on 
the gel. An equal protein amount for each sample was diluted in 5xSDS sample buffer and MQ 
water to a total concentration of 1xSDS sample buffer to denaturate the proteins. The samples were 
heated at 96°C for 5 min to reduce disulphide linkages.
The running chamber was prepared and filled with running buffer. The samples and the 
standard were transferred to the wells using a pipette with loading tips. Voltage was applied, first 
160 V for 5 min to compress the proteins in the stacking gel and next 120 V for 2 – 2 ½ h to 
separate the proteins by size in the separation gel. 
3.2.4 Protocol for Western blotting
The membrane (Amersham HybondTM-P, PVDF) was activated by incubation with methanol for 5 
min. The membrane with the separation gel on top was placed in blotting cassette, the cassette was 
transferred to the blotting chamber and blotting buffer poured over to cover the cassette. A magnet 
stirrer and a cooling system were used to obtain circulation in the liquid and avoid melting of the 
gel. Finally, the proteins were blotted onto the membrane using a current of 200 mA for 16 – 18 h, 
the membrane facing the positive pole and the gel facing the negative pole.
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The membrane was washed with PBS Tween for 5 min and non-specific binding of antibody 
to the membrane was blocked by incubation with blocking buffer (WB2) for 1 – 2 h. Next, the 
membrane was incubated with primary antibody, see Table 3.4 for anti-FOLR2 antibody and Table 
3.5 for anti-PSMA antibody preparation. The FOLR2 and PSMA blots were incubated at 4°C over 
the night, for 16 – 18 h.
The membrane was washed with PBS Tween for 4x15 min and next incubated with alkaline 
phosphatase-coupled secondary antibody anti-rabbit 1:20 000 diluted in WB2 solution for 2 h at 
room temperature. The secondary antibody and incubation times were identical for the FOLR2 and 
PSMA blots. The membrane was washed with PBS Tween for 4x15 min, incubated with 1xDEA for 
2x2 min and next with substrate solution for 20 min with minimal light exposure. Finally, images of 
the blot were processed using a Fujifilm LAS 3000 Imager and the Image Reader LAS-3000 
software was used to control the instrument and to process images.
An actin measurement was next performed on the same blot by following the same 
procedure as described for FOLR2 and PSMA. First, the blot was stripped by incubation with Re-
blot solution for 15 min, followed by blocking and incubation with anti-actin primary antibody 1:10 
000 (see Table 3.6 for contents) for 24 – 72 h at 4°C. Next, the blot was washed and incubated with 
secondary antibody alkaline phosphatase-coupled anti-mouse 1:10 000 diluted in WB 2 for 2 hours 
at room temperature shaking. The blot was washed again, incubated with 1xDEA and finally 
substrate solution for 20 min before processing of images.
All incubations of the blot were performed while shaking, using an Edmund Bühler Swip 
shaker. 
Table 3.4: FOLR2 antibody solution preparation, 1 μg/ml
Ingredient Amount for 1 μg/ml (recommended dilution)
Anti-FOLR2: ab56067 (abcam) 500 μg/ml 10 μl
WB 2 (blocking buffer) 5 ml
Table 3.5: PSMA antibody solution preparation, 1.25 μg/ml
Ingredient Amount for 1.25 μg/ml 
(recommended dilution 1-3 μg/ml)
Anti-PSMA: AB10614 (Millipore) 250 μg/ml 30 μl
WB 2 (blocking buffer) 5 ml
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Table 3.6: Actin antibody 1:10 000 solution preparation
Ingredient Amount
Actin antibody 3 μl
WB2 (blocking buffer) 30 ml
3.3 Transient transfection of PSMA in the PC-3 cell line
3.3.1    Protocol for PSMA transfection by lipofectamine
Plasmids encoding GFP (supplied by prof. James Lorens, Univ. Bergen), PSMA (supplied by prof. 
Dean Bacich, Univ. Pittsburgh) or empty vector (supplied by prof. James Lorens, Univ. Bergen) 
were maxi-prepped by Nina Lied Larsen. PC-3 cells were cultured in a NuncTM 6-well tissue culture 
dish four days prior to the transfection, and had reached about 90% confluence at the day of 
transfection. 2 ml DMEM medium supplemented with 10% FBS but without antibiotics was added 
to each well and 4 tubes were prepared using ingredients described in Table 3.7 and 3.8. The 
contents of Tube 1 and 2 and the contents of tube 3 and 4 were mixed thoroughly, i.e. the DNA-
solutions were mixed with the lipofectamine-solutions, and incubated at room temperature for 20 
min. Next, 500 μl of the DNA-lipofectamine mixture was added to each well; 3 wells were 
transfected with PSMA (4 μg/well) and GFP (0.4 μg/well)-encoding DNA and another 3 wells with 
empty vector (4 μg/well) and GFP (0.4 μg/well)-encoding DNA. GFP was used as a means of 
visualising successful transfection. The wells were incubated at 37°C, 6% CO2 for 6 h, and the 
medium was changed to fresh RPMI-1640 supplemented with 10% FBS and antibiotics. GFP 
expression was detected after 24 h by examination in a Zeiss Axiovert 200M Fluorescence/Live cell 
imaging microscope using a FITC laser, see Figure 4.20 for GFP-positive cells. Cells for 
experiments were detached by trypsin treatment and reseeded in 48-well tissue culture dishes. Cell 
lysates for Western blotting were prepared (see section 3.2.1) from the contents of two 6-well 
dishes, one transfected with PSMA and one with empty vector.
Table 3.7: Lipofectamine transfection ingredients for 3 wells: PSMA – encoding DNA + 10% GFP 
– encoding DNA 
Tube number Ingredient Amount for 3 
wells, μg
Concentration, 
μg/μl
Amount of 
solution for 3 
wells, μl
1 GFP – DNA 1.2 1 1.2
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PSMA – DNA 12 1.1 10.91
DMEM medium 
(- FCS, - P/S)
- - 738
2 Lipofectamine - - 30
DMEM medium 
(- FCS, - P/S)
- - 720
Table 3.8: Lipofectamine transfection ingredients for 3 wells: Empty vector – DNA + 10% GFP – 
encoding DNA
Tube number Ingredient Amount for 3 
wells, μg
Concentration, 
μg/μl
Amount of 
solution for 3 
wells, μl
3 GFP – DNA 1.2 1 1.2
Empty vector – 
DNA 
12 0.7 17.14
DMEM medium 
(- FCS, - P/S)
- - 732
4 Lipofectamine - - 30
DMEM medium 
(- FCS, - P/S)
- - 720
3.3.2 Protocol for PSMA transfection by calcium phosphate
PC-3 cells were cultured in a NuncTM multidish 6-well two days prior to transfection, and had 
reached about 70% confluence at the day of transfection. 2 ml DMEM medium supplemented with 
10% FBS but without antibiotics and 2 μl 25 mM chloroquine was added to each well. Transfection 
reagents containing plasmids were prepared, see contents in Table 3.9 and 3.10. 2xHEPES buffer 
was added as the last ingredient followed by aeration of the solutions for 20 – 30 s. Immediately 
after this, 500 μl of the solutions was added to each well; 3 wells were transfected with the PSMA 
(2 μg) and GFP-encoding DNA (0.2 μg) and another 3 wells with empty vector (2 μg) and GFP-
encoding DNA (0.2 μg). The wells were incubated at 37°C, 6% CO2 for 5 – 6 h and the medium 
was changed to fresh RPMI-1640 supplemented with 10% FBS and antibiotics. The wells were 
incubated for a total time of 48 h after the transfection and examined for GFP expression as 
described in section 3.4.1. See Table 2.10 for the contents of 2xHEPES buffer. 
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Table 3.9: Calcium phosphate transfection ingredients for 3.2 wells: PSMA and 10% GFP-
encoding DNA
Ingredient Amount for 1 well, μg Concentration Amount of solution for 
3.2 wells, μl
GFP – DNA 0.2 1 μg/μl 6.4*
PSMA – DNA 2 1.1 μg/μl 5.82
MQ water - - 685
CaCl2 - 2 M 102.4
2xHEPES buffer - - 800
*A 1:10 dilution of GFP-encoding DNA was made
Table 3.10: Calcium phosphate transfection ingredients for 3.2 wells: empty vector and 10% GFP-
encoding DNA
Ingredient Amount for 1 well, μg Concentration Amount of solution for 
3.2 wells, μl
GFP – DNA 0.2 1 μg/μl 6.4*
Empty vector – DNA 2 0.7 μg/μl 9.15
MQ water - - 682
CaCl2 - 2 M 102.4
2xHEPES buffer - - 800
*A 1:10 dilution of GFP-encoding DNA was made
3.4 Cell experiments
3.4.1 Protocol for cell experiments with suspension cell lines
Cells were seeded in the desired concentration (40000 – 300000 cells/well) in a 12 or 48-well tissue 
culture dish. Next, drug or liposome solutions were added to the wells, and the plate was incubated 
at 37°C, 6% CO2 for 20 or 30 min. The cells were washed 3 times by this procedure: the plate was 
centrifuged at 160 x g in a Heraeus Labofuge 400 centrifuge for 4 min, medium was gently 
removed and fresh medium was added. The cells were next incubated at 37°C, 6% CO2 for 24 or 48 
h and WST-1 viability assay was performed as described in section 3.5.3. The cells were fixed by 
addition of 4% FIX solution to a final concentration of 2% FIX. DNR was added to the fixative (0.1 
μg/ml) as a fluorescent probe to stain the nuclei for cell counting. See Table 2.10 for contents of 4% 
FIX solution and 4% FIX solution with DNR. 
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3.4.2 Protocol for cell experiments with adherent cell lines
Cells were seeded in the desired concentration (3000 – 5000 cells/well) in a 48-well tissue culture 
dish one or two days before the experiment was performed. At the day of the experiment, the 
medium was replaced with fresh medium, next drug or liposome solutions were added to the wells 
and the plate was incubated at 37°C, 6% CO2 for 30 min. The cells were washed 2 times by 
removing the medium and adding fresh medium. Next the cells were incubated at 37°C, 6% CO2 for 
48 or 72 h, and WST-1 viability assay was performed as described in section 3.5.3. The cells were 
fixed by addition of 4% FIX solution to a final concentration of 2% FIX. To stain the nuclei, either 
DNR was added to the fixative (0.1 μg/ml) or a 1:100 dilution of Hoechst 33342 in MQ water was 
added to the wells after fixing. The DNR staining turned out to be more powerful compared to 
Hoechst 33342 staining, and was therefore chosen as staining reagent in further experiments. See 
Table 2.10 for contents of 4% FIX solution and 4% FIX solution with DNR.
3.4.3 Cell proliferation reagent WST-1 measurements and calculations
Roche Cell proliferation Reagent WST-1 was added to the wells to a total 1:20 dilution in the tissue 
culture dishes containing cells. Two or three wells containing the medium only was added WST-1 
and used as blanks. The dish was shaken gently and incubated at 37°C, 6% CO2 for 2 h. The 
absorbance was measured at 450 nm with 620 nm as reference using an ASYS UVM 340 
microplate spectrophotometer and the software DigiRead or ScanPlus was used to control the 
instrument and perform measurements. 
Calculations:  See calculations formula 1 for calculation of adjusted absorbance of treated 
divided by adjusted absorbance of control cells. The average values of the parallels for different 
treatments were calculated and a bar graph was made, plotting treatment against treatment/control 
values. For experiments with two parallels, the variation between the measurements was calculated 
by subtracting one of the measurements from the average value and error bars were inserted using 
these values. For experiments with three or more parallels, the standard error was calculated (see 
calculations formula 2 and 3) and error bars were inserted using these values. T-tests were 
performed between comparable treatments with similar doses when three parallels or more were 
performed. P-values were marked in the graph this way: P < 0.05 *, P < 0.01 **, P < 0.005 *** and 
P < 0.001 ****. 
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Calculations formulas:
∣drug treated ∣−∣blank ∣÷∣control ∣−∣blank ∣ (1)
SE=s÷n (2)
s=1÷N−1×∑ xi−x 2 (3)
3.4.4 Fluorescence microscope cell counting, calculations and processing of images
Counting of cells was performed using a Zeiss Axiovert 200M Fluorescence/Live cell imaging 
microscope. The nucleus morphology was examined using DNR or Hoechst 33342 as a fluorescent 
probe, at 40x or 20x cy3.5 for DNR and 40x or 20x DAPI for Hoechst. See Figure 4.11 for DNR 
staining in MOLM-13 wt cells and Figure 4.18 for Hoechst staining in LNCaP cells and. Cells 
having condensed or fragmented nuclei were counted as dead and cells having whole nuclei were 
counted as living at the time of fixing. For adherent cell lines, cell death was also determined on the 
basis of the appearance of the cells in the light microscope; cells that had a rounded appearance, 
surface membrane blebs, were detached from the wells and/or had a destroyed cell membrane were 
counted as dead. A minimum of 100 cells were counted per well unless otherwise specified. 
Calculations: The percentage of dead cells was calculated for all parallels (see calculations 
formula 4), and the adjusted % cell death for different treatments calculated by using calculations 
formula 5 to account for cell death among the controls. The average values of the parallels for 
different treatments were calculated and a bar graph was made, plotting treatment against adjusted 
% cell death values. Error bars were made and T-tests were performed as described in section 3.5.3.
Images of the cells were obtained by the software AxioVision 3.1, using the Zeiss 
microscope described at 40x magnification. Phase contrast, and the cy3.5, DAPI and FITC lasers 
were used.
Calculations formulas:
Cell death=Dead÷DeadLiving ×100 (4)
Adjusted cell death= cell death− cell death control ×100÷100− cell deathcontrol  (5)
3.4.5  Flow cytometry cell experiment
MOLM-13 SH p53 cells were used for a flow cytometry-analysis experiment. Liposomes with the 
Texas Red fluorochrome as described in Table 3.13 and 3.14 were made by Lars Herfindal. 300000 
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cells/well were seeded in a 12-well tissue culture dish and liposomes were added at 3%, 1% and 
0.3% of the total volume in 2 parallels per liposome batch (PEG and PEG-FA). The plate was 
incubated for 10 min at 37°C, 6% CO2. Washing of the cells was performed twice as described in 
section 3.5.1 and the plate was incubated for 30 min at 37°C, 6% CO2. Next, the cell suspensions 
were washed with PBS twice and the cell pellets finally re-suspended in 300 μl 2% FIX. Flow 
cytometry was performed using an Accuri® C6 Flow cytometer, 3 blue and 1 red laser at FL3, 
610/20 filters. The instrument was controlled by and data analysis was performed using the FlowJo 
software. 
3.5 Preparation and measurements of liposomes
3.5.1 Preparation of liposomes
HEPC, cholesterol and DSPE-PEG were weighed out and dissolved in chloroform separately. See 
Table 3.11 – 3.14 for contents of different liposome batches of 5 ml, all the batches had a molar 
ratio of 1,81 HEPC : 1 cholesterol : 0,15 DSPE-PEG.  The ingredients were mixed and for FA-
conjugated liposomes, the DSPE-PEG-FA dissolved in ethanol was added. A thin, even lipid film 
was made by evaporation of the chloroform in a Rotary Evaporator at 150 mBar, ~ 90 rpm and the 
film was left at maximum vacuum pump capacity for 30 – 60 min to remove all chloroform. The 
lipid film was rehydrated in 250 mM ammonium sulphate pH 5.5 (see Table 2.10) by vortexing at 
60 – 65°C, which is above the lipid transition temperature. 15 – 20 clean glass beads (0.45 mm) 
were used to aid the rehydration. Next, the flask with the hydrated multi-lamellar vesicles (MLV) 
was gently shaken under heating (90 – 100 rpm, 60°C) for 30 min to ensure mixing of the contents. 
Finally the MLV were extruded through Whatman® Nucleopore® track-etch membranes for lipid 
extrusion at 65°C using a Northern Lipids LIPEXTM extruder 5 times at 0.8 and 0.4 μm 5 times, and 
10 times at 0.2 and 0.1 μm. This created monolamellar liposomes of a size between 110 and 124 nm 
in diameter. The particle size was measured before, during and after lipid extrusion by Dynamic 
Light Scattering (DLS, see section 3.6.3). 
To change the buffer on the outside of the liposomes, the liposome solution was gel filtrated 
(see section 3.6.2) through a 1.5x15 cm BioRad Econo-Column filled with Sephadex TM G-25 
Medium. Fractions of 1 ml were gel filtrated using PBS pH 8 as eluting buffer and the column was 
washed with 30 ml PBS between each fraction. Based on previous experiments (Herfindal, 
Univ.Bergen 2011, pers.comm.), the liposomes were diluted 1.6 times during the extrusion and gel 
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filtration, and the lipid concentration in the liposome solution was 2.7 mg/ml (Herfindal, 2011 
pers.comm.). 
Next, the cytostatics were incorporated into the liposomes, using the acid precipitation 
method. This method takes advantage of that the drugs are neutral in slightly alkaline solutions, but 
protonated in acidic solutions (see Figure 1.6), hence when the drugs are internalised they can no 
longer pass the lipid bilayer and precipitates (69). 1 mg DNR and/or 1 mg EME per 10 mg lipids 
was added to the liposome suspensions, and the mixtures were incubated at 60°C for 2 h. The 
mixtures were shaken every 30 min. 
The liposomes were then gel filtrated to remove non-incorporated cytostatics from the 
liposome solutions, and eluted in PBS pH 7.4. The column was washed with 100 – 150 ml PBS 
between each liposome fraction to wash out cytostatics from the column. 
Liposomes were stored dark at 4°C to prevent chemical degradation. Liposome solutions 
were always shaken before use, and used for a maximum of 2 months after they were prepared. 
Table 3.11: PEGylated liposomes, 5 ml batch
Ingredient Amount
HEPC (Hydrogenated Egg Phosphatidylcholine) 12.0 mg
Cholesterol 3.2 mg
DSPE-PEG (1,2-Disteraoyl-sn-glycero-3-
Phosphoetanolamine-N-[Methoxy(Polyethylene 
glycol)-2000] (ammonium salt)
3.5 mg
Table 3.12: Folic acid conjugated PEGylated liposomes, 5 ml batch
Ingredient Amount
HEPC (Hydrogenated Egg Phosphatidylcholine) 12.0 mg
Cholesterol 3.2 mg
DSPE-PEG (1,2-Disteraoyl-sn-glycero-3-
Phosphoetanolamine-N-[Methoxy(Polyethylene 
glycol)-2000] (ammonium salt)
3.5 mg
DSPE-PEG-FA (1,2-disteraoyl-sn-glycero-3-
phosphoetanolamine-N-((polyethylene glycol-
5000)folate) (ammonium salt)
140 μl
Table 3.13: PEGylated liposomes with the Texas red fluorochrome, 5 ml batch
Ingredient Amount
HEPC (Hydrogenated Egg Phosphatidylcholine) 12.0 mg
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Cholesterol 3.2 mg
DSPE-PEG (1,2-Disteraoyl-sn-glycero-3-
Phosphoetanolamine-N-[Methoxy(Polyethylene 
glycol)-2000] (ammonium salt)
3.5 mg
Texas Red® DHPE (Texas Red® 1,2 
Dihexadecanoyl-sn-Glycero-3-
Phosphoethanolamine, Triethyl ammonium salt)
0.25 mg
Table 3.14: Folic acid conjugated PEGylated liposomes with the Texas red fluorochrome, 5 ml  
batch
Ingredient Amount
HEPC (Hydrogenated Egg Phosphatidylcholine) 12.0 mg
Cholesterol 3.2 mg
DSPE-PEG (1,2-Disteraoyl-sn-glycero-3-
Phosphoetanolamine-N-[Methoxy(Polyethylene 
glycol)-2000] (ammonium salt)
3.5 mg
DSPE-PEG-FA (1,2-disteraoyl-sn-glycero-3-
phosphoetanolamine-N-((polyethylene glycol-
5000)folate) (ammonium salt)
140 μl
Texas Red® DHPE (Texas Red® 1,2 
Dihexadecanoyl-sn-Glycero-3-
Phosphoethanolamine, Triethyl ammonium salt)
0.25 mg
3.5.2 Preparation of columns and gel filtration of liposomes
Two BioRad Econo-Columns at 1.5x15 cm and 0.7x10 cm were prepared by heating Sephadex TM 
G-25 Medium and MQ water 1:2 to 90°C for 1 h. The mixture was shaken every now and then. 
Next, Sephadex was washed two times with MQ water and the mixture was transferred to the 
column using a pipette. The mobile phase was then exchanged to PBS.
All solutions were degassed before introducing them into the column. The 1.5x15 and 
0.7x10 cm columns were washed before use by gel filtrating at least 30 and 5 ml eluting buffer, 
respectively. A fraction of empty liposomes was gel filtrated to fill up unspecific binding of 
liposomes to the column. Empty liposomes and liposomes containing EME were identified as an 
opaque solution when eluted out, whereas DNR-containing liposomes were visible as a red band in 
the column. The column was left standing with 20% ethanol when not used for over three days to 
avoid bacterial contamination.
As a quality assurance and indication of stability, fractions of the readily prepared liposomes 
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containing DNR were gel filtrated after a time of storage. Any leakage of DNR from the liposomes 
would be visible due to the red colour of the drug. The liposomes were gel filtrated on a small 
column using degassed PBS (pH 7.4) as the eluting buffer. 
3.5.3 Size and zeta potential (ZP) measurements
A Malvern Zetasizer Nanoseries Nano-ZS with Zetasizer software was used for the size and zeta 
potential (ZP) measurements. In this instrument, the particle size is measured by dynamic light 
scattering (DLS) (70). DLS measures Brownian motion of particles, i.e. the random movement due 
to bombardment of solvent molecules, and relates this to the particle size (70). The diameter 
measured by DLS is the hydrodynamic diameter of a particle, since it refers to particle movement in 
a fluid (70). The Zetasizer uses the M3-PALS technique to determine the ZP (71). In this technique, 
the particle electrophoretic mobility is measured, which is related to the ZP by the Henry equation 
(71).
Size measurements: Samples for DLS size measurements were prepared by diluting one 
drop of liposome suspension in 1 ml suspension buffer (PBS or ammonuim sulphate). The sample 
was transferred to a Brand disposable cuvette. Lipids were chosen as material and dispersant set to 
PBS when dissolved in PBS or water when dissolved in ammonium sulphate. Three measurements 
were performed for each sample and the data were presented as Z-average value (nm, diameter) and 
polydispersity index (PdI). 
ZP measurements: The liposome suspension was diluted 1:10 in 5% sucrose. With this 
solvent, we obtained reliable results and the size was relatively stable. PBS or diluted PBS (1:10) as 
solvent did not give consistent results. The sample was injected into a clear disposable zeta cuvette 
and the cuvette was placed in the Zetasizer instrument. Settings were changed in the software to ZP 
measurements. Lipids were chosen as material and dispersant set to water. Three measurements 
were performed for each sample. Next, the size was measured, using the same sample in the same 
cuvette. The data were presented as ZP (mV), ZP standard deviation for the ZP and Z-average (nm, 
diameter) for size measurements.
3.5.4    Drug content measurements
DNR content measurements: Samples were prepared by mixing thoroughly 100 μl of 
liposome or free DNR solution, 500 μl of 20% SDS (see table 2.10 for content) to lyse the 
liposomes and 400 μl PBS in a Brand disposable cuvette. Blank samples contained 500 μl 20% SDS 
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and 500 μl PBS. Measurements were done by a Varian Cary UV-visible spectrophotometer at 483 
nm controlled by the CaryWin UV program in simple reads mode. The measurements were zeroed 
out at the blank sample, after this three measurements were made for each liposome sample. A DNR 
standard curve was made based on measurements of solutions of free DNR (10, 30, 60 and 100 μM) 
using linear regression. The equation for the straight line obtained was used to calculate the DNR 
content in the liposome samples. The absorbance of empty liposomes at 483 nm was subtracted 
from the absorbance of DNR-containing liposomes before calculations were done.
EME content measurements: Samples were prepared by mixing 75 μl of liposome or free 
EME solution and 75 μl of 20% SDS to lyse the liposomes.  Blank samples contained 75 μl milli Q 
water and 75 μl 20% SDS. The samples were transferred to a Starna® Cary quartz cuvette and the 
absorbance was measured at 280 nm using a Varian Cary UV-visible spectrophotometer in the 
CayWin UV program, scan mode. An EME standard curve was made based on measurements of 
solutions of free EME (3, 10, 30, 60, 100 and 150 μM). The absorbance of the samples at 500 nm 
and the absorbance of the blank sample was subtracted from the free EME samples, and these 
values were plotted for the making of a standard curve. A straight line was obtained using linear 
regression and the equation was used to calculate the EME content in the liposome samples. The 
absorbance of empty liposomes at 280 nm was subtracted from the absorbance of EME-containing 
liposomes before calculations were done.
3.5.5 Phosphatidylcholine (PC) content measurements
A Phosphatidylcholine Assay Kit from Cayman Chemical Company was used to determine the PC 
content of the liposomes. First, the PC buffer, PC colour detector and the PC enzyme mixture were 
prepared as described by the supplier. The PC standard and 7 tubes with increasing PC 
concentration (0, 20, 40, 60, 80, 100 and 150 mg/dl) were prepared for the making of a standard 
curve and next the reaction mixture was prepared. In a 96-well multidish, two 10 μl parallels of 
each of the PC standards and three 10 μl parallels of undiluted liposome samples (PEG-FA and 
PEG-conjugated empty liposomes) were added. 100 μl of reaction mixture was added to each well, 
and the plate was shaken carefully to mix the contents. The plate was incubated at 37°C for 60 min 
and the absorbance measured at 585 – 600 nm in an ASYS UVM 340 microplate 
spectrophotometer. The software DigiRead was used to perform measurements and control the 
instrument.
Calculations were performed and a standard curve was made. All samples and the standard 
solutions were subtracted the absorbance of the blank solution. A standard curve was made based on 
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the subtracted absorbance values of the standards and a straight line was obtained using linear 
regression. The equation was used to calculate the PC contents in the liposome samples. 
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4. Results
4.1 Liposome drug loading and characteristics
Four different liposome batches were used in the work performed in this master thesis; Batch 1 
(02.11.11), 2 (03.01.12) and 3 (12.03.12) consisted of PEG and PEG-FA liposomes (see Table 3.11 
and 3.12). Batch 4 consisted of PEG Texas Red and PEG-FA Texas Red liposomes (see Table 3.13 
and 3.14), these liposomes were not filled with cytostatics. All batches were made as described in 
section 3.6.1. 
4.1.1 Liposome production: Characteristics, size measurements and estimation of  
PC content
After rehydration of the lipid film, the multilamellar large vesicles (MLV) solution had an opaque 
white appearance. This rehydrated solution precipitated and formed white aggregates when stored 
over night dark at 4°C and the aggregates were easily re-suspended when shaken. After the last 
extrusion (100 nm pore size), the liposome solution became less opaque, and did not form visible 
aggregates upon storage in the dark at 4°C. 
The liposomes typically had a Z-average value of between 110 and 124 nm in diameter, and 
a low polydispersity index (PdI), usually below 0.05 (Table 4.1). The Texas Red-conjugated 
liposomes (batch 4) were somewhat larger in size (Table 4.1) Table 4.2 shows that both the Z-
average and PdI values of the liposomes decrease during the extrusion, resulting in a monodisperse 
liposome solution. Figure 4.1 shows a typical size distribution curve. 
Table 4.1: Z-average values for liposome batches 1, 2, 3 and 4 (Texas Red) after lipid extrusion
Liposomes Batch 1 Batch 2 Batch 3 Batch 4 (Texas Red)
Z-
average, 
d, nm
PdI Z-
average, 
d, nm
PdI Z-
average, 
d, nm
PdI Z-
average, 
d, nm
PdI
PEG 121.6 0.021 116.5 0.045 114.6 0.062 130.2 0.065
PEG-FA 110.7 0.039 119.0 0.025 123.8 0.068 126.3 0.065
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Table 4.2: Z-average values for liposome batch 3 before, during and after lipid extrusion as an 
example of how the particle size and PdI changed during lipid extrusion
Extruded through 
filter
PEG liposomes PEG-FA liposomes
Z-average, d, nm PdI Z-average, d, nm PdI
Before extrusion 2220.0* 0.513 6290.0* 1.000
800 nm x5 450.6** 0.308 579.6** 0.487
400 nm x5 133.8 0.117 176.6 0.161
200 nm x10 131.5 0.083 208.1** 0.226
100 nm x10 114.6 0.062 123.8 0.068
Feedback from Zetasizer software:
* = Measurement results did not meet quality criteria
** = Multiple peaks in measurements 
Figure 4.1: Size distribution curve for liposome batch 3 measured by DLS. The graph shows a  
typical size distribution for liposomes after lipid extrusion through a 100 nm membrane; PEG-
liposomes after 100 nm extrusion are shown here. Three measurements are shown. The Z-average  
and PdI is the result for the first measurement.
In order to obtain the correct relationship between lipid and drug when the liposomes were 
to be loaded with DNR and EME, we measured the total PC content of the extruded liposomes. 
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However, the measurement results were below the dynamic range of the PC kit (20 – 150 mg/dl, see 
Figure 4.2) and the standard deviation of the three measurements performed for each liposome 
fraction was high (Table 4.3). An estimate of the PC content before gel filtration can be calculated 
by dividing the added PC (15.5 mg) by 5 ml, which gives a PC content of 3.1 mg/ml (310 mg/dl). 
Even though liposomes were gel filtrated before the PC content measurements, the measurement 
results of this batch were too low to be correct: 0.019 and 0.037 mg PC /ml (1.9 and 3.7 mg/dl). 
Previous measurements performed by Lars Herfindal showed that the lipid content of gel filtrated 
liposomes was 2.7 mg lipids/ml solution and this was used as an estimate in the further work with 
this thesis, for instance in calculations when loading liposomes with drugs.
Table 4.3: PC concentration measurement results for liposome batch 2 after buffer exchange gel  
filtration.
Liposomes PC concentration, mg/dl Standard deviation, mg/dl
PEG 1.926 1.63
PEG-FA 3.685 5.99
Figure 4.2: Phosphatidylcholine (PC) standard curve. 
4.1.2 Drug loading of liposomes and drug content measurement results
The appearance of the drug-incorporated and gel filtrated solutions was colourless but slightly 
turbid for EME-containing liposomes and pink and slightly turbid for the DNR-containing 
liposomes. 
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The DNR and EME standard curves are shown in Figure 4.3 and 4.4, respectively. Results of 
calculated DNR and EME contents for liposome batches 1 – 3 are shown in Table 4.4. Due to 
previous experiences with difficulty in measuring EME content of liposomes (Herfindal 2011, 
pers.comm), these measurements were not performed on the first batch. The EME content of batch 
1 is therefore estimated as the average of batch 2 and 3.
Figure 4.3: Daunorubicin standard curve. DNR absorbance measured at 483 nm
Figure 4.4: Emetin standard curve. EME absorbance measured at 280 nm
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Table 4.4: Drug content of liposome batch 1, 2 and 3. The EME content of batch 1 is estimated as  
the average of batch 2 and 3.
Liposomes Batch 1 Batch 2 Batch 3
[DNR], μM [EME], μM [DNR], μM [EME], μM [DNR], μM [EME], μM
PEG DNR 57.00 - 95.82 - 64.90 -
PEG-FA 
DNR
47.54 - 56.54 - 65.59 -
PEG EME - 131.59 - 115.07 - 148.11
PEG-FA 
EME
- 132.61 - 113.14 - 152.07
PEG 
DNR+EME
36.77 66.15 74.86 45.01 77.03 87.29
PEG-FA 
DNR+EME
33.08 92.53 52.18 89.80 69.59 95.25
4.1.3 Characterisation of drug-loaded liposomes: Size and zeta potential  
measurements and stability during storage
Size measurements were performed after drug-loading and gel filtration of the liposomes. Results 
for the different batches are shown in Table 4.5 – 4.7. When comparing to Table 4.1, it can be seen 
that the Z-average of the liposomes does not seem to change much after drug-loading. A small 
increase in size is seen for batch 3, for batch 2 the size is fairly constant. For batch 1, the size is also 
fairly constant except from the measurement of PEG liposomes with DNR+EME. 
Table 4.5: Size measurement results of liposome batch 1 after drug-loading.
Liposomes
PEG PEG-FA
Z-average, d, nm PdI Z-average, d, nm PdI
Empty 123.3 0.055 111.2 0.054
DNR 123.7 0.084 113.2 0.058
EME 121.2 0.056 112.1 0.048
DNR+EME 183.5* 0.221 120.0 0.106
Feedback from Zetasizer software:
* The sample could be sedimenting during measurement (count size and rate decreasing). This 
measurement had two peaks. If the peak in the large area could be excluded from the measurements, 
the Z-ave could be more similar to the others.
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Table 4.6: Size measurement results of liposome batch 2 after drug-loading and after 39 days of  
storage.
Liposomes
PEG: 
After drug-loading
PEG-FA:
After drug-loading
PEG:
After 39 days storage
PEG-FA:
After 39 days storage
Z-
average, 
d, nm
PdI Z-
average, 
d, nm
PdI Z-
average, 
d, nm
PdI Z-average, 
d, nm
PdI
Empty 116.0 0.038 117.3 0.041 117.7 0.056 119.1 0.045
DNR 113.8 0.033 118.9 0.030 113.7 0.042 119.6 0.055
EME 116.8 0.039 119.1 0.035 117.5 0.055 121.5 0.055
DNR+EME 114.2 0.040 119.0 0.048 116.3 0.051 121.2 0.055
Table 4.7: Size measurement results of liposome batch 3 after drug-loading.
Liposomes
PEG PEG-FA
Z-average, d, nm PdI Z-average, d, nm PdI
Empty 116.3 0.038 126.0 0.041
DNR 116.4 0.053 127.4 0.023
EME 118.5 0.046 126.2 0.058
DNR+EME 116.4 0.048 126.0 0.029
To investigate the electronegativity of the liposomes and to see if this was influenced by drug 
loading, we measured the ZP. This was only done for batch 3, since the application was not 
available when batch 1 and 2 were made. Interestingly, the ZP increased from -26 mV in empty 
liposomes to between -10 and -15 mV in drug-loaded liposomes (Table 4.8). The liposomes had to 
be suspended in 5% sucrose in order to obtain reliable results and we experienced only a modest 
increase in size (Table 4.8), suggesting that the liposomes were intact. Liposomes suspended in 
hypotonic solution (10% PBS) underwent a large increase in size, the size increased substantially 
during the measurements and a large peak at approximately 5000 nm size suggested that aggregates 
were formed. These findings imply that the liposomes were lysed in hypotonic solution. When 
using undiluted PBS as solvent for ZP measurements, we were not able to obtain high enough count 
rates to get reliable data, and the estimated ZP differed from those reported in the literature. 
Probably, the ionic strength of PBS was too high to make it an appropriate solvent for these 
measurements. High conductivity media suppress the electrical double layer, also called the Debye 
length, and this in turn increases the ZP (70, 71). This is consistent with our findings, as the 
measured ZP was approximately -6 mV with PBS as a solvent.
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Table 4.8: Zeta potential measurements for liposome batch 3. 5% sucrose was used as solvent. Size  
measurements were performed directly after zeta potential measurements.
Liposomes
PEG PEG-FA
ZP, mV Standard 
deviation 
ZP, mV
Z-average, 
d, nm
ZP, mV Standard 
deviation 
ZP, mV
Z-average, 
d, nm
Empty -25.5 1.15 131.8 -26.2* 1.45 156.0*
DNR -13.6 0.07 127.5 -14.6 1.98 149.6*
EME -14.7 0.57 129.9 -12.1 0.71 135.9
DNR+EME -9.9 1.02 129.0 -12.1 0.07 142.1
Feedback from Zetasizer software:
* Sample not stable or not clean
Stability of the liposome solutions during storage was investigated by visual inspection, size 
measurements and gel filtration of DNR-loaded liposomes. Drug-loaded and empty liposomes were 
observed for a storage period of up to 4 months dark at 4°C and for this period of time they did not 
form visible aggregates and the colour and appearance remained constant. Size measurements were 
performed on batch 2 for a storage period of 39 days after drug-loading (Table 4.6). The liposome 
size remained fairly constant over this period of time, and some increase was seen in PdI value. 
Gel filtration of DNR-containing liposomes was performed for batch 2 after a storage period 
of 39 days after drug incorporation. No free DNR was visible in the column during the gel filtration; 
the liposome solution eluted as a single pink band for all fractions. The same observation was noted 
for batch 3 after a storage period of 40 days after drug incorporation. In conclusion, the liposomes 
do not seem to suffer from DNR leakage over a period of time of 40 days.
4.2 Efficacy of drug-loaded multifunctional liposomes against AML cell lines
4.2.1      Comparing the efficacy of drug-loaded liposomes conjugated with PEG-FA to  
liposomes conjugated with PEG only in MOLM-13 and MV4-11 cells
We first investigated the efficacy of liposomes in the MOLM-13 and MV4-11 leukaemia cell lines 
in a pilot experiment, see Figure 4.5 and 4.6. 
The EME and DNR doses given by the different liposomes (PEG and PEG-FA) are nearly 
equivalent and therefore the results are comparable. Both cell lines suffered cell death from 
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treatment with drug-loaded liposomes at concentrations below 0.30 μM DNR, 1.25 μM EME and 
0.32/0.57 μM DNR+EME. Cell death was higher for PEG-FA liposomes than PEG liposomes. Also, 
cell death was substantially higher for the MV4-11 cell line than the MOLM-13 cell line for nearly 
equivalent DNR and EME doses. Treatment with empty liposomes with or without FA did not 
appear to affect cell viability or induce death (Figure 4.5 and 4.6). 
The cell viability WST-1 results were not consistent (Figure 4.5 A and B, Figure 4.6 A and 
B). For the MOLM-13 cell line, there was more conversion of the tetrazolium salt, i.e. metabolic 
activity when treated with PEG-EME and PEG-DNR+EME than for empty liposomes. There was 
no apparent metabolic activity for PEG-DNR liposomes, while the counting of cells on nuclear 
morphology for this treatment showed approximately 30% cell death. The results for PEG-FA 
treatment in this cell line were more consistent with fluorescence microscopy cell counting, but 
with no apparent metabolic activity for the PEG-FA-DNR treatment (Figure 4.5).
For the MV4-11 cell line, the WST-1 data showed high metabolic activity for the cells 
treated with empty liposomes. There were no apparent viable cells for the PEG-DNR, PEG-
DNR+EME, PEG-FA-DNR, PEG-FA-EME and PEG-FA-DNR+EME treatments and some 
metabolic activity for the PEG-EME treatment (Figure 4.6 A and B). These results were fairly 
consistent with the fluorescence microscopy cell counting, except from that the EME-liposomes 
induced only around 15% cell death (Figure 4.6 C and D). 
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Figure 4.5: Death induction in MOLM-13 wt cells by different liposomes. Cells (44000 cells/well)  
were incubated with liposomes (batch 1) for 30 min in 12-well tissue culture dishes, washed 3  
times, and incubated for 72 h before WST-1 measurement and fixing of cells. The cells were  
cultured in FA-free medium for 4 days before the experiment and the experiment was conducted in  
FA-free medium. Panel A and B show results from WST-1 measurements, panel C and D results  
from fluorescence microscope cell counting using Hoechst 33342 as a fluorescent probe. The data  
are average of two parallels and the deviation.
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Figure 4.6: Death induction in MV4-11 cells by different liposomes. Cells (42000 cells/well) were  
incubated with liposomes (batch 1) for 30 min in 12-well tissue culture dishes, washed 3 times, and  
incubated for 72 h before WST-1 measurement and fixing of cells. The cells were cultured in FA-free  
medium for 4 days before the experiment and the experiment was conducted in FA-free medium.  
Panel A and B show results from WST-1 measurements, panel C and D results from fluorescence  
microscope cell counting using Hoechst 33342 as a fluorescent probe. The data are average of two 
parallels and the deviation. 
4.2.2       Expression of folate receptor β (FOLR2) in MOLM-13 cells
Based on the results shown above, it was decided to use the MOLM-13 cells to evaluate the 
usefulness of the FA-conjugated liposomes in AML therapy. These cells showed a somewhat better 
response towards the FA-conjugated liposomes and also higher tolerance to different media than the 
MV4-11 cells. We found no previous studies that showed expression of FR-β in MOLM-13 cells, 
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and therefore wanted to verify the expression by Western blotting. SDS-PAGE and Western blotting 
was performed on MOLM-13 wt and MOLM-13 SH p53 (silenced p53) cell lines. The cells were 
cultured in medium with and without FA to investigate if FA depletion could influence the level of 
FR-β expression. As a negative control, we used HEK293 cells.
The FR-β blot was difficult to interpret (Figure 4.7). We identified a band most likely to be 
FR-β, but other bands were also present. The FR-β seemed to be expressed in both MOLM-13 cell 
lines, with no visible difference in expression between cells grown in medium with or without FA. 
The SDS-PAGE and Western blotting procedure was performed a total of three times with the same 
results. We suspect that the low intensity of the bands corresponding to FR-β can be due to poor 
quality of the anti-FOLR2 antibody: apparently it had been stored at 4°C rather than -20°C (supplier 
recommendations (72)) for 2 years. 
Figure 4.7: Expression of FOLR2 in MOLM-13 cells. A: FOLR2 Western blot. 50 μg protein was 
loaded for each sample. Lane A is MOLM-13 wt cultured in RPMI medium and lane B the same cell  
line cultured in FA-free medium for 33 days. Lane C is MOLM-13 SH p53 cultured in RPMI  
medium and lane D the same cell line cultured in FA-free medium for 4 days. Lane E is HEK293 as  
a negative control (cell lysate provided by Lene Myhren). B: Actin measurements performed on the  
same blot.
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4.2.3 Evaluating effective dose and establishing difference in effect between PEG-FA-
conjugated liposomes vs PEG-conjugated liposomes in MOLM-13 wt and MOLM-13 SH 
p53 cells
We next wanted to find the effective dose of DNR and EME in liposomes to induce cell death in 
MOLM-13 cells. It has previously been shown that leukaemia cells with deficient p53 are 
particularly sensitive to the combination of DNR and protein synthesis inhibitors (60). The MOLM-
13 variant with silenced p53 (MOLM-13 SH p53) was therefore introduced in the experiments. 
We found that PEG-FA-conjugated liposomes were more effective than PEG-conjugated 
liposomes in delivering both DNR, EME and the DNR+EME combination. A higher proportion of 
cell death was induced by PEG-FA-conjugated liposomes. This was true for both cell lines (Figure 
4.8 – 4.10). The DNR+EME combination was found to induce less cell death than DNR alone. Also 
there was some batch-to-batch variation, liposome batch 2 seemed to be more effective than batch 3 
(Figure 4.8 and 4.9). Comparing results between the cell lines, the MOLM-13 SH p53 cells were 
more vulnerable to liposome treatment than MOLM-13 wt cells (Figure 4.8 – 4.10).
In these experiments, we noted that the WST-1 data were not reliable. Figure 4.8 A and B 
show typical WST-1 data as examples of the inconsistent data obtained by using this assay. 
Fluorescence microscopy using DNR as a fluorescent probe (Figure 4.8 C and D, images in Figure 
4.11) was considered a much more reliable method for death assessment. 
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Figure 4.8: Death induction in MOLM-13 wt cells by different liposomes. Cells (40000 cells/well)  
were incubated with liposomes (batch 2) for 30 min in 48-well tissue culture dishes, washed 3  
times, and incubated for 48 h before WST-1 measurement and fixing of cells. The cells were  
cultured in FA-free medium for 42 days before the experiment and the experiment was conducted in  
FA-free medium. Panel A and B show results from WST-1 measurements, panel C and D results  
from fluorescence microscope cell counting on nucleus morphology using DNR as a fluorescent  
probe. The data are average of two parallels and the deviation.
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Figure 4.9: Death induction in MOLM-13 wt cells by different liposomes. Identical design and 
execution as described in Figure 4.8, but a different liposome batch was used (batch 3). WST-1  
measurements were performed, but are not included here due to inconsistent results. The cells were 
cultured in FA-free medium for 36 days before the experiment and the experiment was conducted in  
FA-free medium. Panel A and B show results from fluorescence microscope cell counting on nucleus  
morphology using DNR as a fluorescent probe. The data are average of two parallels and the  
deviation.
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Figure 4.10: Death induction in MOLM-13 SH p53 cells by different liposomes. Cells (40000  
cells/well) were incubated with liposomes (batch 2) for 30 min in 48-well tissue culture dishes,  
washed 3 times, and incubated for 48 h before fixing. WST-1 measurements were performed, but are  
not included here due to inconsistent results. The cells were cultured in FA-free medium for 4 and 5  
days before the experiment and the experiment was conducted in FA-free medium. Panel A and B 
show results from fluorescence microscope cell counting on nucleus morphology using DNR as a  
fluorescent probe. * refers to T-tests between PEG and PEG-FA treatments, while # refers to T-tests  
performed within the same liposome treatment. The data are average of four parallels (combined  
results from identical experiment performed on two different days) and the standard error. 
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Figure 4.11: Cell and nucleus morphology of the MOLM-13 wt cell line treated with PEG-
liposomes. A: control cells, B: DNR (0.96 μM) treated cells, C: EME (2.11 μM) treated cells, D: 
DNR+EME (0.96+1.09 μM) treated cells. Images to the left show surface morphology by phase  
contrast illumination, images to the right show nucleus morphology of nuclei stained with DNR, at  
laser cy3.5. Apoptosis morphology is characterised by condensed chromatin structures in a  
fragmented nuclei. In the light microscope, apoptotic cells are typically characterised by cell  
shrinkage, membrane blebs and an irregular surface.
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Figure 4.12: Nucleus morphology of the MOLM-13 wt cell line treated with PEG and PEG-FA 
conjugated liposomes: PEG-FA conjugated liposomes were more effective in inducing cell death  
than PEG conjugated liposomes. DNR was used to stain the nuclei for fluorescence microscopy.  
Images to the left show treatment with PEG-liposomes, images to the right PEG-FA-liposomes. A:  
DNR (0.96 μM) treated cells, B: DNR (0.96 μM) treated cells, C: EME (2.11 μM) treated cells, D:  
EME (2.08 μM) treated cells, E: DNR+EME (0.96 + 1.09 μM) treated cells, F: DNR+EME (0.96 + 
1.31 μM) treated cells. Apoptosis morphology as described in Figure 4.11.
4.2.4 Optimisation of treatment regime with PEG-FA-conjugated liposomes
PEG-FA liposomes were established as more effective than PEG liposomes. We next wanted to 
investigate further for optimisation of PEG-FA-liposome treatment of AML cells by sequential 
incubation of liposomes. This was done on the basis of the work by Gausdal et al., who found that 
the protein synthesis inhibitor CHX was most effective when given after DNR addition (60).
PEG-FA liposomes loaded with DNR and PEG-FA liposomes loaded with EME were used 
in a pilot experiment performed in MOLM-13 cell lines (Figure 4.13). Adding PEG-FA-EME 
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liposomes subsequent to PEG-FA-DNR incubation was indeed more effective than incubation with 
both liposomes at the same time. The sequential incubation was also more effective than PEG-FA-
DNR liposomes alone, but this difference was not statistically significant. 
Figure 4.13: Death induction in MOLM-13 cells by PEG-FA-conjugated liposomes, sequential  
incubation. A: MOLM-13 wt, B: MOLM-13 SH p53. Cells (40000 cells/well) were incubated in 48-
well tissue culture dishes with liposomes (batch 2) for 20 min, series 5 (DNR FA + #EME FA#):  
PEG-FA DNR only, all series were washed 3 times, series 5 was incubated with PEG-FA EME for  
20 min, series 5 was washed 3 times, and finally all series incubated for 48 h before fixing of cells.  
The MOLM-13 wt and MOLM-13 SH p53 cells were cultured in FA-free medium for 9 and 15 days  
before the experiment was performed, respectively, and the experiment was conducted in FA-free  
medium. Panel A and B show results from fluorescence microscope cell counting on nucleus  
morphology using DNR as a fluorescent probe. The data are average of three parallels and the  
standard error. 
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We next decided to perform an extended experiment with additional doses of EME to 
investigate optimisation of doses. MOLM-13 SH p53 cells were chosen for the experiment because 
they seemed to be most vulnerable to liposome treatment (Figure 4.13).
This experiment did not show any statistically significant difference in effect for sequential 
incubation compared to simultaneous adding of liposomes (Figure 4.14). For the two lowest EME 
concentrations, simultaneous adding of liposomes seemed to be more effective, while sequential 
incubation was clearly most effective for the highest EME concentration. Sequential incubation was 
more effective than PEG-FA EME alone and PEG-FA DNR alone, except from in the lowest EME 
concentration where PEG-FA DNR alone appeared to be slightly more effective. 
Figure 4.14: Death induction in MOLM-13 SH p53 cells, sequential incubation with PEG-FA-
conjugated liposomes. Cells (40000 cells/well) were incubated in 48-well tissue culture dishes with  
liposomes (batch 3) for 20 min, series 5 (DNR FA + #EME FA#): PEG-FA DNR only, all series  
were washed 3 times, series 5 was incubated with PEG-FA EME for 20 min, series 5 was washed 3  
times, and finally all series were incubated for 48 h before fixing of cells. The cells were cultured in  
FA-free medium for 8 days before the experiment was performed, and the experiment was  
conducted in FA-free medium. Results from fluorescence microscope cell counting on nucleus  
morphology using DNR as a fluorescent probe. The data are average of three parallels and the  
standard error. 
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4.2.5 Comparing the effect of free cytostatics against liposome-encapsulated  
cytostatics in MOLM-13 SH p53 cells
The effect of DNR and EME-incorporated liposomes in the MOLM-13 cell lines was clearly 
demonstrated, and it was also shown that PEG-FA liposomes were more effective than PEG-
liposomes. However, it was desirable to compare the effect of liposomal drugs with the drugs in free 
form. An experiment was done based on DNR and EME doses given in a previous experiment (see 
Figure 4.10), and the design was ensured to be identical. Direct comparison between the effect of 
liposomal and free drug was now possible.
The free drug was clearly most effective for DNR and DNR+EME-treatments (Figure 4.15). 
For EME-treatments, however, PEG-FA-conjugated liposomes were in fact more effective than free 
drug, and the difference was statistically significant for the 2.08 μM dose. 
Figure 4.15: Cell death induction by free DNR and EME in MOLM-13 SH p53 cells. The  
experimental design and execution was identical to that described in Figure 4.10, therefore the  
results are comparable. The cells were cultured in FA-free medium for 31 days before the  
experiment and the experiment was conducted in FA-free medium. Results from fluorescence  
microscope cell counting on nucleus morphology using DNR as a fluorescent probe. The data are  
average of three parallels and the standard error. * refer to when free cytostatics are most effective,  
# to when liposomal cytostatics are most effective; PEG-conjugated liposomes/PEG-FA-conjugated  
liposomes.
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4.2.6 Flow cytometry of PEG and PEG-FA containing fluorescent liposomes
The flow cytometry experiment was performed to investigate the uptake of liposomes into MOLM-
13 SH p53 cells. We wanted to investigate the extent of uptake of liposomes, and also see if there 
was a difference in uptake of PEG-FA liposomes compared to PEG-liposomes, which the results 
from previous experiments suggested. 
The results from this experiment are not shown graphically. In summary, we were not able to 
identify Texas Red fluorescence in any of the prepared samples compared to the control cells, 
suggesting that the liposomes were not taken up. 
4.3   Evaluation of the efficacy of liposomes in PC-3 and LNCaP prostate cancer cell 
lines
Another cancer that is associated with over-expression of folic acid binding surface proteins is 
prostate cancer (41). We therefore wanted to test efficacy of the liposomes on the prostate cancer 
cell lines PC-3 and LNCaP. The LNCaP cell line is known to endogenously express PSMA (41, 42), 
a possible target for FA-conjugated liposomes (see section 1.2.2), whereas the PC-3 cell line does 
not (42). On the other hand, PC-3 cells have deficient p53 (66), which could make them more 
sensitive to the combination of DNR and protein synthesis inhibitor. 
4.3.1. Efficacy of PEG-FA-conjugated liposomes vs PEG-conjugated liposomes in  
LNCaP and PC-3 prostate cancer cell lines
A pilot experiment was performed to investigate the efficacy of liposomes in prostate cancer cell 
lines. Nearly equivalent doses of cytostatics were given so that results were comparable between 
PEG-FA and PEG-conjugated liposomes. The experimental design and execution was identical for 
the PC-3 and LNCaP cell line.
Results for the PC-3 cells are shown in Figure 4.16. Empty liposomes were shown to have 
no effect on cell viability or cell death. Drug-incorporated liposomes induced cell death and reduced 
cell viability at concentrations below 8.22 μM EME, 0.53 μM DNR and 0.54+0.98 μM DNR+EME. 
Cell viability and cell counting results correlated well. PEG-FA liposomes were more effective than 
PEG liposomes. The DNR+EME combination was more effective than the drugs given separately 
for PEG-FA-conjugated liposomes, and the combination was somewhat less effective compared to 
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DNR alone for PEG-conjugated liposomes. Figure 20 shows cell and nucleus morphology of the 
PC-3 cell line, with DNR used as a fluorescent probe.
Results for the LNCaP cells are shown in Figure 4.17. The findings were essentially the 
same as for the PC-3 cells. Empty liposomes had no effect on cell viability and death, and the drug-
incorporated liposomes induced cell death and reduced cell viability at concentrations lower than 
2.17 μM EME, 0.53 μM DNR, and 0.54+1.52 μM DNR+EME. Cell viability and cell counting 
results correlated well. PEG-FA-conjugated liposomes were clearly more effective than PEG-
liposomes. The cells seemed to be more vulnerable to DNR treatment than EME treatment. Figure 
4.18 shows cell and nucleus morphology of LNCaP cells using Hoechst 33342 as a fluorescent 
probe. 
Figure 4.16:  Death induction in PC-3 cells by different liposomes. Cells (3000 cells/well) were  
seeded in a 48-well tissue culture dish 2 days before the experiment. The cells were incubated with  
liposomes (batch 1) for 30 min, washed 2 times, and incubated for 72 h before WST-1 measurement  
and fixing of cells. Panel A and B show results from cell viability assay WST-1, panel C and D show 
results from cell counting on cell and nucleus morphology using Hoechst 33342 as a fluorescent  
probe. The data are average of two parallels and the deviation.
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Figure 4.17: Death induction in LNCaP cells by different liposomes. Cells (3000 cells/well) were  
seeded in a 48-well tissue culture dish 2 days before the experiment. The cells were incubated with  
liposomes (batch 1) for 30 min, washed 2 times, and incubated for 72 h before WST-1 measurement  
and fixing of cells. Panel A and B show results from cell viability assay WST-1, panel C and D show 
results from cell counting on cell and nucleus morphology using Hoechst 33342 as a fluorescent  
probe. The data are average of two parallels and the deviation.
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Figure 4.18: Cell and nucleus morphology of LNCaP cells treated with PEG-conjugated liposomes.  
Images to the left show surface morphology by phase contrast illumination. Images to the right  
show nucleus morphology using Hoechst 33342 as a fluorescent probe. Panel A: control cells,  
panel B: DNR (2.05 μM) treated cells, panel C: EME (8.22 μM) treated cells, panel D: DNR+EME 
(2.08+3.74 μM) treated cells. 
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4.3.2. Enforced expression of PSMA in the PC-3 cell line and evaluation of  
liposome efficacy
We next wanted to investigate if enforced expression of PSMA made PC-3 cells more vulnerable to 
liposome treatment. 
First, a transient transfection of the PC-3 cell line with PSMA using calcium phosphate was 
attempted without success. Very few cells were transfected; only 20 cells per well in a 6-well tissue 
culture dish 48 h after the transfection. Experiments were not performed with these cells. 
Next, a transient transfection of the PC-3 cells with PSMA was performed using 
lipofectamine. Half of the cells were transfected with empty vector to serve as a control in cell 
experiments. GFP was co-expressed as a marker for transfection efficiency. The transfection was 
quite successful, with 25% of the cells expressing GFP. GFP expression was estimated by cell 
counting in the fluorescence microscope (see pictures Figure 4.20).
Cell lysates for Western blotting were made with the aim of confirming PSMA expression. 
SDS-PAGE and Western blot was executed with help from Nina Lied Larsen. The blot showed very 
weak bands (Figure 4.19). However, two bands could be seen for LNCaP cells, the positive control, 
in an area consistent with the size of PSMA (Figure 4.19, lane 2). Bands were detected for NRK 
cells and all PC-3 cell samples (Figure 4.19, lane 1, 3, 4 and 5) at a different size, but 
disappointingly no band could be detected verifying PSMA-expression for the transfected PC-3 
cells (lane 5). A possible explanation is that there were not enough transfected cells present in the 
PC-3 sample for a band to be detected. The blot could also indicate that the cells were not 
transfected with PSMA, as GFP is co-transfected in a separate plasmid, and can be expressed 
independently of PSMA.
Figure 4.19: Western blot of PSMA. Lane 1: NRK cells used as a negative control, lane 2: LNCaP 
cells used as a positive control, lane 3: PC-3 cells, lane 4: Empty vector-transfected PC-3 cells,  
lane 5: PSMA-transfected PC-3 cells. Arrows indicate bands for PSMA in lane 2. 45 μg protein was 
loaded on the gel for each sample. Actin measurement was not performed.
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Figure 4.20: PC-3 cells transfected with GFP and PSMA, treated with drug-loaded PEG-
conjugated liposomes. Images to the left show surface morphology by phase contrast illumination.  
Images in the middle show GFP-expressing cells, detected by the FITC laser. Images to the right  
show nucleus morphology using DNR as a fluorescent probe. A: Control cells, B: DNR (2.13 μM) 
treated cells , C: EME (2.41 μM) treated cells, D: DNR+EME (2.13+2.41 μM) treated cells.
Next, a cell experiment was performed on the transfected cells. The PEG-FA-conjugated 
liposomes were more effective for both PSMA-transfected and empty vector-transfected control 
cells and the difference in efficacy between the two cell types was not as large as expected (Figure 
4.21). However, the transfection efficiency was only 25% judged by GFP-positive cells, only 50 
cells were counted per well and PSMA was not successfully detected by Western blot (Figure 4.19). 
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Figure 4.21: Comparison of the efficacy of liposomes between PSMA-transfected PC-3 cells and 
PC-3 control cells transfected with empty vector. Cells (5000 cells/well) were seeded in a 48-well  
tissue culture dish one day before the experiment. The cells were incubated with liposomes (batch  
3) for 30 min, washed 2 times, and incubated for 48 h before fixing of cells. WST-1 measurements  
were performed but are not included here. Panel A and B show results for PSMA-transfected cells.  
Panel C and D show results for empty vector-transfected cells. DNR was used as a fluorescent  
probe for cell counting based on nucleus morphology (see figure 4.21). Only GFP-positive cells  
were counted, at least 50 cells per well. The data are average of two parallels and the deviation. 
4.4 Effect of PEG-FA-conjugated liposomes on non-malignant cells
We next wanted to investigate if PEG-FA-conjugated liposomes could enhance drug effects in non-
malignant cells. The NRK cell line was used for this purpose. The experimental design was 
identical to the experiment with prostate cancer cells described in Figure 4.21.  
Results are shown in Figure 4.22. WST-1 results showed decreased metabolic activity for 
cells treated with liposomes containing EME and DNR+EME, and PEG-FA-liposomes seemed to 
give a larger decrease in metabolic activity than PEG liposomes. The decrease in metabolic activity 
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seen for EME and DNR+EME was not reflected entirely by cell counting. Results from 
fluorescence cell counting on nuclear morphology showed that PEG liposomes did not cause any 
cell death in the given concentrations. PEG-FA liposomes caused some cell death (10%) for the 
highest concentrations of DNR and EME. In comparison, MOLM-13 cell lines experienced 60 – 
80% cell death at a DNR concentration of 0.96 μM (batch 2, PEG-FA liposomes) and 60 – 75% cell 
death at an EME concentration of 2.08 μM (batch 2, PEG-FA liposomes). The LNCaP and PC-3 cell 
lines experienced 100% and 60% cell death at a DNR concentration of 2.03 μM (batch 1, PEG-FA 
liposomes) and 25% and 50% cell death at an EME concentration of 8.29 μM (batch 1, PEG-FA 
liposomes), respectively. 
In summary, liposome-incorporated cytostatics was seen to be far more cytotoxic for 
leukaemia and prostate cancer cell lines than for the non-malignant NRK cell line. Presence of FA 
on the liposomal surface enhanced drug efficiency also in NRK cell lines. 
Figure 4.22: Death induction by liposomes in a non-malignant cell line: NRK cells. Cells (5000  
cells/well) were seeded in a 48-well tissue culture dish 24 h before the experiment was performed.  
Cells were incubated with liposomes (batch 3) for 30 min, washed 2 times, and incubated for 48 h  
before WST-1 measurements and fixing of cells. Panel A and B show results from WST-1  
measurements, panel C and D show results from fluorescence cell counting on nucleus morphology  
using DNR as a fluorescence probe. The data are average of three measurements and the standard 
error. 
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5. Discussion
5.1 Production of multifunctional liposomes
We were able to produce liposomes that combined several desirable properties for cancer treatment. 
The liposomes were PEGylated for minimal MPS recognition, prolonging circulation times in vivo. 
We were able to successfully incorporate DSPE-PEG-FA into the liposomes, creating FA-coated 
liposomes that enabled targeted drug delivery via FR-β and PSMA. Also, we were able to 
incorporate two cytostatics into a single liposome, obtaining a drug carrier for two different drugs. 
A synergistic effect of the drugs could thus be investigated by this system.
All the desired properties were incorporated into a single liposome, enabling targeted drug 
delivery and favourable alteration of pharmacokinetic properties of the drugs. The liposomes were 
designed to be stable and retain the cytostatics inside; thereby protecting cytostatics from 
degradation and elimination, and also protecting healthy tissues from the cytostatics, reducing toxic 
side-effects. This is especially promising for AML treatment with DNR, which suffers from serious 
cardiotoxic adverse effects (56). 
For the empty liposomes, the measured ZP was substantially lower than for the drug-
incorporated liposomes (see Table 4.8). This could be due to association of positively charged drug 
molecules (see Figure 1.6) to the negatively charged DSPE-PEG (73, 74) on the outside of the 
liposomes. Suspensions with a Zeta potential higher than +30 mV or lower than -30 mV are 
normally considered to exhibit colloidal stability (71). Our measurement results indicate that the 
liposome suspensions will aggregate over time, and it is more likely that drug-incorporated 
liposomes will aggregate since this zeta potential is closer to zero compared to the zeta potential of 
empty liposomes. However, flocculation or sedimentation was never visually observed for empty or 
drug-loaded liposome suspensions, the particle size was constant and PdI increased only slightly 
during 39 days of storage (Table 4.6). We therefore consider the colloidal stability to be satisfactory 
over the period of time that the liposomes were used. The suspensions were shaken before use to re-
suspend liposome aggregates if any should be present. 
The size of the liposomes increased modestly after suspending in sucrose. We consider the 
most likely explanation to be due to the low ionic strength of sucrose compared to PBS, which the 
liposomes normally have been suspended in. Low conductivity media extends the electrical double 
layer and hence the measured hydrodynamic diameter of the liposomes, which is measured by DLS 
(70). Supporting this view is the fact that the liposome size remained constant over three 
measurements. The size increase could also be due to sucrose molecules absorbing to the PEG 
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chains or, less likely, caused by leakage of water molecules over the lipid bilayer into the liposome 
core. Another factor that could affect our results both for ZP and size measurements is the viscosity 
of the medium (70, 71). Water was set to solvent during the measurements since sucrose was not an 
option in the software, and the viscosity of sucrose solution is higher than that of water (75-77).
The drug content of the liposomes was seen to vary among the batches, and the measured 
EME concentration was higher than the DNR concentration (Table 4.4). This phenomenon could be 
explained by the gel filtration. Since collection of liposomes were by visual inspection of the elute, 
the fractions containing DNR, which had a red colour, were larger than the un-coloured EME 
liposome fractions. For batch 3, the yielded fractions were 2.1 ml EME-liposomes and 3.5 ml DNR-
liposomes. Hence, the DNR-containing fractions were more diluted and the concentration was 
lower. Also, EME could be located in the lipid bilayer due to its structural resemblance to 
cholesterol (see chemical structure of EME in Figure 1.5), which could contribute towards a higher 
apparent encapsulation efficiency for this drug. The incorporation of two drugs simultaneously 
turned out to be especially difficult to reproduce in terms of concentrations. Batch-to-batch 
variation was also seen to some extent in terms of size (Table 4.1). 
No apparent drug-release was noted from the DNR-containing liposomes after 39 days of 
storage at 4°C in the dark. Drug-release was estimated by visual observation during gel filtration, 
and theoretically DNR could be retained in the column in low concentrations that were not visible. 
Therefore, a future improvement would be measuring drug leakage of the liposomes quantitatively. 
Stability testing performed by Herfindal on liposomes in serum at 37°C for 24 h showed that the 
DNR content did not decrease substantially (unpublished data). The drug-leakage of EME-
containing liposomes was not measured since EME is un-coloured, making the gel filtration method 
impossible to use. Therefore the stability of these liposomes was not investigated as thoroughly as 
for DNR-containing liposomes. Drug-release of EME-containing liposomes needs to be 
investigated in the future. 
PC content measurements of the liposomes were attempted without success (Table 4.3). 
There are several possible explanations to why we were not able to obtain reliable measurement 
results. Liposomes are composed of phospholipid bilayer membranes, and lysis of the liposomes is 
necessary for PC detection. The results suggest that the liposomes were not lysed. We suspect that 
the PEGylation of the liposomes could contribute to this. The PEG chains could induce sterical 
hindrance for the enzymatic reaction with PC, and this need to be subjected for the assay to work in 
our system. Cholesterol is also a part of our liposome formulation, which makes the packing of the 
phospholipids denser (48). This could make lysis of the liposomes more difficult.
The liposomes were used for up to 8 weeks after they were made, and it must be taken into 
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consideration that the stability in a time period over 39 days was strictly not tested. It would 
strengthen the experimental design if this had been performed routinely. More extensive stability 
testing of the liposomes is a future area of investigation. However, the results from the 
measurements at 39 days strongly suggested that the liposomes were stable for a longer period of 
time since no aggregates were detected and the size did not increase substantially (Table 4.5). In 
conclusion, for the use in this thesis we consider that the liposomes showed sufficient stability.
A flow cytometry experiment was performed to investigate the cellular uptake of liposomes. 
We were not able to detect a difference in emitted fluorescence between control cells and cells 
treated with liposomes. A possible explanation could be the very short incubation time of 10 min. A 
study showed that FA-conjugated liposomes were associated to FA-expressing cells within 30 min, 
and after 50 min incubation time receptor-mediated liposomal internalisation was observed (29). It 
is also possible that the washing procedures following the short incubation time were too vigorous. 
On the other hand, experiments performed on LNCaP cells showed liposomal uptake on confocal 
microscopy with an incubation time of 10 min (Herfindal 2012, pers.comm.). We also suspect that 
the laser and filter settings of the flow cytometer might have been wrong. Finally, there is a 
possibility that there was something wrong with the liposome batch or the Texas Red fluorochrome. 
In summary, we were able to produce multifunctional liposomes that showed sufficient 
stability for the use in this thesis.
5.2 Efficacy of multifunctional liposomes in FR-expressing AML cell lines
PEG-FA-conjugated liposomes were clearly more effective than the PEG-conjugated liposomes in 
AML cell lines (Figure 4.5 and 4.8 – 4.10). A literature search did not reveal any studies that 
reviewed the expression of FR-β in MOLM-13 cells. However, we confirmed by Western blotting 
(Figure 4.7) that the MOLM-13 cell lines expressed FR-β, which indicated that targeted drug 
delivery was achieved via this receptor. The bands for the blot were weak, other bands were present 
and the FR antibody was suspected to be of poor quality due to wrong storage conditions. Western 
blot was performed on MV4-11 cells, a cell line known to express FR-β (22), with similar results 
(data not shown). Still, by Western blotting we detected a band that corresponds to the size of FR-β 
(Figure 4.7), and the results from our experiments strongly suggest the presence of functional FR 
due to the improved efficacy of PEG-FA-conjugated liposomes compared to PEG-conjugated 
liposomes. There was no visible difference in expression level between cells cultured in FA-free and 
FA-containing medium, although culturing in FA-free medium can induce up-regulation of FR (16).
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Targeted drug delivery to AML cells via FR-β has been performed in several studies (22, 
23), and our results confirm the success of this strategy. This in vitro success is promising for 
further animal experiments, and possibly in the future leading to a new treatment for AML. 
Liposomal drug delivery also has the potential of reducing the serious side-effects associated with 
the standard AML treatment, especially regarding to anthracycline cardiotoxitciy (56, 58). This 
could warrant the opportunity of treating more patients older than 60 years, a group of patients with 
very low disease survival (5). 
Data suggest that AML originates from leukaemic stem cells (LSCs), a rare population of 
cells capable of self-renewal, proliferation and differentiation (11, 24). Cytarabin is notably 
ineffective against LSCs, and there is a need for targeted strategies to kill these cells (11). Since FR-
β is frequently co-expressed with CD34 in AML cells, it is likely that LSCs express functional FR-β 
(15, 23). Therefore, FR-targeted liposomes could offer a means of targeting LSCs. It was 
demonstrated by Li and co-workers that FA-conjugated liposomes filled with doxorubicin decreased 
colony forming units in AML cells, suggesting that these liposomes could be used to target LSCs 
(22). 
Cell cytotoxicity was the end point of measurement in the AML cell lines. Empty liposomes 
had no effect on cell cytotoxity, so the liposomes themselves were not considered a confounding 
factor in the interpretation of the results. WST-1 measurement results on the MOLM-13 cell lines 
gave inconsistent readings, and we concluded that fluorescence microscopy was the most reliable 
method, with cell death morphology as the end point. The WST-1 cell viability assay is dependent 
on the activity of mitochondrial enzymes of the cells. If a cell line has a generally low 
mitochondrial activity, the conversion of the tetrazolium salt will be low, and small differences in 
activity will have a large impact on the results. This could be a possible explanation to our results. 
Also, rupture of lysosomes could increase WST-1 turnover and produce false positive results. 
The incubation time with liposomes was set to 20 or 30 min for all experiments. A study of 
targeted drug delivery in AML cells using FA-conjugated liposomal DOX reported an incubation 
time of 2 h (22). The relatively short incubation times used in this thesis provides a strict test for 
drug delivery via multifunctional liposomes, valuable for future in vivo experiments. Since we 
found a distinct increase in activity when using PEG-FA-conjugated liposomes with these relatively 
short incubation times, we conclude that this drug delivery device has potential also in in vivo 
experiments. 
Two identical experiments were performed on the MOLM-13 wt cell line using two different 
liposome batches (Figure 4.8 and 4.9). The trend was clearly the same in both experiments: PEG-
FA-conjugated liposomes were more effective than PEG-conjugated liposomes. This shows that we 
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were able to obtain similar results between different liposome batches.  However, the first 
experiment (Figure 4.8) had a more pronounced difference in effect compared to the second 
experiment (Figure 4.9), which is likely to be due to the above-mentioned batch-to-batch variations. 
When comparing the effect of the free cytostatics and liposomal cytostatics, it was seen that 
DNR was clearly more effective when given in free form. Another study reported that free DOX 
was found to be more toxic compared to PEG-FA-conjugated liposomal DOX in AML cells (22). 
DNR has been shown to inhibit parts of the endocytosis-machinery (unpublished data, Gausdal). 
This could explain our results, since FA-PEG-conjugated liposomes are internalised by FR receptor-
mediated endocytosis (27). Free DNR enter cells via passive diffusion over the cell membrane (23), 
while liposomes are dependent on internalisation by endocytosis, which is inhibited by the drug it is 
carrying. Supporting this view is that EME was more effective in PEG-FA-conjugated liposomal 
form than in free form. In summary, by using liposomal DNR instead of free DNR, the toxicity is 
decreased. This can be transferred to healthy tissues, where potentially serious side-effects such as 
cardiotoxicity can be reduced.
In summary, our results in the AML cell lines were encouraging for further investigation of 
multifunctional liposomes targeting the FR.
5.3 Efficacy of multifunctional liposomes in prostate cancer cell lines
The multifunctional liposomes were effective also in prostate cancer cell lines (Figure 4.16, 4.17 
and 4.21). The effective cytostatics concentrations were higher than for the AML cell lines. The FA-
PEG-conjugated liposomes were demonstrated to be more effective than the PEG-conjugated 
liposomes. 
The LNCaP cell line showed a better response towards PEG-FA-conjugated liposomes than 
the PC-3 cell line (Figure 4.16 and 4.17), and LNCaP cells seemed to be most sensitive for DNR 
treatment. LNCaP cells are known to express PSMA (41), which was our target for drug delivery by 
the PEG-FA-conjugated liposomes in this cell line. PSMA expression was confirmed by Western 
blotting, as shown in Figure 4.19. The results from our LNCaP experiments overall suggest that 
PSMA can be used as a target for drug delivery, and that this was successfully achieved. We do not 
know the mechanism for PEG-FA-conjugated liposomal uptake via the PSMA, but receptor-
mediated endocytosis is a plausible mechanism (41). This could be investigated in future 
experiments. The sensitivity of LNCaP cells towards DNR offers a potentially new chemotherapy 
treatment for advanced prostate cancer. Targeted delivery of chemotherapeutics could be a future 
82
preferred approach compared to hormone therapy, which is associated with numerous side-effects 
and development of resistant cells (36).
PC-3 cells were transfected with PSMA, but it is not sure whether the transfection was 
successful. The transfection procedure still needs optimisation. The Western blot did not show any 
band for PSMA in the transfected cells (Figure 4.19), possibly due to low concentrations of 
successfully transfected cells or problems with solubilisation of membrane proteins. The experiment 
performed with the PSMA-transfected cells showed only a modest, if any, increase in sensitivity 
towards PEG-FA-conjugated liposomes compared to the response seen for control cells (Figure 4.16 
and 4.21), suggesting that the transfection efficiency for PSMA was low.
Despite the limited amounts of experiments showed in this thesis, the results from the 
LNCaP cells indicates PSMA as a target for drug delivery via FA-conjugated liposomes, and that 
DNR could be an effective drug in prostate cancer therapy. 
5.4 Comparing the effect of DNR and DNR+EME in multifunctional liposomes
The effect of the DNR+EME combination was investigated on the basis of the work performed by 
Gausdal et al. (60). The DNR+EME combination was found to be less effective than DNR alone in 
MOLM-13 cells (Figure 4.8 – 4.10). This was true both for wt cells and cells with silenced p53, and 
there was no apparent difference in response towards the combination of drugs between the cell 
lines. However, we can not exclude the possibility that cell death occurred with a morphology we 
were unable to detect. The phenomenon of a “frozen” death type is described in AML cell lines by 
Gausdal et al. in a similar situation (60). In this study, the protein synthesis inhibitor CHX was seen 
to block visible signs of apoptosis induced by DNR, because the cells underwent massive 
conventional apoptosis after removal of the drug combination (60). This death morphology is not 
easily detected in the microscope. Unfortunately no other reliable method than cell counting on 
nucleus morphology was used for the AML cell lines, so if this phenomenon occurred it could have 
been overlooked. In future investigations cell death should be detected using other reliable methods, 
such as flow cytometry, ATP measurements, annexin/propidium iodide staining or LDH release 
measurements.
In PC-3 cells, the DNR+EME combination was more effective for PEG-FA-conjugated 
liposomes (Figure 4.16). In LNCaP cells, the effect for the combination was equal to DNR alone 
(Figure 4.17). PC-3 has defective p53, while LNCaP has intact p53 (66). Hence, these results were 
consistent with previous experience that cells with defective p53 seem to be more vulnerable to the 
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combination of DNR and a protein synthesis inhibitor (60) (Gausdal, 2012, unpublished data). This 
response demonstrates why transfection with PSMA of the PC-3 cell line was performed; 
theoretically allowing for an even better response towards PEG-FA-conjugated liposomes and the 
combination of drugs compared to the LNCaP cell line.
In the AML cell lines, sequential incubation of PEG-FA-conjugated liposomes containing 
DNR and EME was performed (Figure 4.13 and 4.14). Interestingly, the combination of drugs was 
seen to be more effective than DNR alone when sequentially incubated. This was consistent with 
findings by Gausdal et.al. (60). In this thesis, we found that the effect seemed to be concentration-
dependent, because the relationship was not found to be true for lower EME concentrations (Figure 
4.14). Administrating drugs sequentially is an approach that can be easily transferred to the clinic. 
The potential of improved therapeutic outcome that is suggested by sequential incubation can 
ultimately lead to a higher proportion of cured AML patients.
EME has been demonstrated to be a P-gp substrate, which could in part explain synergistic 
and additive effects between the drugs (65). Also, this means that combining other drugs with EME 
exhibits the potential of overcoming MDR, which is a common problem in cancer therapy (59). 
However, another aspect to take into consideration regarding combining DNR and EME for cancer 
therapy is the cardiotoxicity of both drugs. This was issue problematised by Larsson et al., who 
stated that the two drugs should not be used in combination (65). This, however, was discussed for 
drugs in free form, which is not comparable to drugs encapsulated in nanocarriers. Nanocarriers are 
useful in this setting to reduce toxicity, and can potentially allow for combining any drugs that are 
useful for cancer therapy.
An anthracycline was chosen for liposomal encapsulation with the aim of optimising an 
existing treatment form for AML. It is an advantage that DNR is a part of AML treatment, making 
the road to clinical use shorter. As described in section 1.4, EME is approved for use in humans and 
has a shorter way towards approval compared to other protein synthesis inhibitors. The role of 
combining DNR and EME for AML treatment and optimisation of treatment regimes is an issue for 
further investigation. 
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5.5 Conclusion and future investigations
An in vitro validation of multifunctional liposomes has been performed. Liposomes were 
successfully produced, and confirmed to have the desirable properties in terms of targeting 
leukaemia cancer cells in vitro. The liposomes were also demonstrated to be effective in prostate 
cancer cell lines. FR-expressing AML cell lines and a PSMA-expressing prostate cancer cell line 
were targeted by PEG-FA-conjugated liposomes. 
The PEG-FA-conjugated liposomes also showed some increased toxicity compared to PEG-
conjugated liposomes towards the prostate cancer PC-3 cell line not expressing PSMA (42) and the 
non-malignant NRK cell line (Figure 4.16 and 4.22). This could indicate that the liposomes are 
bound to other folate-binding proteins, or even non-specifically to membrane proteins. This effect 
needs to be investigated further. The NRK cells could be expressing the FR, since the FR-α is 
expressed in the kidney proximal tubules (15).
Future experiments should be performed with the aim of optimising liposome doses and 
treatment regimes, especially sequential incubation with liposomes, and also by exploring different 
incubation times with liposomes. Flow cytometry or confocal microscopy could be performed to 
investigate the uptake of liposomes in cancer cells. In AML cell lines, other reliable methods of 
measuring cell death such as flow cytometry, ATP measurements, annexin/propidium iodide 
staining and LDH release measurements should be applied, especially to investigate the possibility 
of “frozen” cell death for cells treated with a DNR+EME combination. 
An alternative way of increasing FR expression in AML cell lines, is by ATRA treatment 
(22). This could be applied to investigate if an increase in effect of PEG-FA-conjugated liposomes 
was achieved.
The multifunctional liposomes produced in this thesis have several areas of future 
investigations. Stability testing should be performed on a regular basis and over a longer period of 
time to evaluate the shelf life. This would include finding a means of measuring EME leakage to 
discover if EME-containing liposomes suffer from this. The zeta potential measurements showed 
interesting results indicating drug association to PEG chains. Evaluating the liposome structure at a 
molecular level would be an interesting future area of investigation. Also, the PC content was never 
measured in these batches. However, the final quality check of the liposomes will be their ability to 
selectively kill malignant cells expressing FA-binding membrane proteins. In our system, this was 
successfully achieved.
In conclusion, targeted drug delivery via multifunctional liposomes has been demonstrated 
to be effective in vitro. Further studies are necessary to explore the efficacy of these liposomes in 
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animal models for cancer. Based on the results presented in this thesis, animal experiments have 
been initiated to investigate if it is possible to prolong life-time of MOLM-13-transplanted mice 
using PEG-FA-conjugated liposomes loaded with DNR or DNR and EME. Many of the advantages 
of targeted drug delivery to cancer cells can not be demonstrated by in vitro studies, such as passive 
targeting via the EPR effect and favourable altering of pharmacokinetic properties of the drug: 
reduction of side-effects, prolonged circulation times, improved therapeutic index and protection of 
the drug from degradation. The above-mentioned animal experiments will investigate these 
advantageous properties of multifunctional liposomes in cancer therapy. 
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